header logo image


Page 494«..1020..493494495496..500510..»

Gene Therapy for Age-related Macular Degeneration Market by global COVID-19 impact analysis, industry trends, business strategies, opportunities and…

June 18th, 2020 8:45 am

The Gene Therapy for Age-related Macular Degeneration Market research report added by Report Ocean, is an in-depth analysis of the latest developments, market size, status, upcoming technologies, industry drivers, challenges, regulatory policies, with key company profiles and strategies of players. The research report compiled by Report Ocean offers the study of market opportunities and market impact that are created due to the COVID-19 pandemic. The overall market impact of COVID-19 can be witnessed in the Q1 2020 but is anticipated to be highly impacted in subsequent quarters in the whole year.

In addition to enlightens the current competitive putting and growth plans enforced with the aid of the Gene Therapy for Age-related Macular Degeneration Market players. Comprehensive secondary research was done to collect information on the market and its parent and ancillary markets. Further, primary research was performed to validate the assumptions and findings obtained from secondary research with key opinion leaders (KOL) and industry experts.

Request Free Sample Report athttps://www.reportocean.com/industry-verticals/sample-request?report_id=mai12777

Gene Therapy for Age-related Macular Degeneration Market Forecast Under COVID-19

Under the public background of the COVID-19 crisis, the industry is being affected by COVID-19. It is currently impossible to accurately predict the degree of control of this epidemic in various countries, and it is impossible to predict whether it will function normally for long-term economic activities.

However, historical data shows that the impact of natural disasters on the macro economy is usually short-term, and the economy often shows a V-shaped trend. Affected by the disaster and market sentiment, the economic growth rate usually drops sharply in a short period of time, but as the disaster is gradually controlled, the market sentiment returns to stability, and the temporarily suppressed consumption and investment needs will be released, resulting in Economic rebound.

Competitive Landscape:

The competitive analysis of major market players is another notable feature of the Gene Therapy for Age-related Macular Degeneration Market report; it identifies direct or indirect competitors in the market.

Key parameters which define the competitive landscape of the Gene Therapy for Age-related Macular Degeneration Market:

Revenue and Market Share by Player

Production and Share by Player

Average Price by Player

Base Distribution, Sales Area and Product Type by Player

Concentration Rate

Mergers & Acquisitions, Expansion

Manufacturing Base

Major players in the global Gene Therapy for Age-related Macular Degeneration market include:RetroSense TherapeuticsAGTCREGENXBIO

Market Segmentation:

Gene Therapy for Age-related Macular Degeneration Market is segmented on the basis of types, on the basis of applications and regions.

Geographical Analysis

Gene Therapy for Age-related Macular Degeneration Market Segment by Regions Consists:

North America (U.S. and Canada)

Europe (UK, Germany, France, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, India, Malaysia, Singapore, Philippines, Indonesia, Thailand, Vietnam)

South America (Brazil, Argentina, Mexico, and Rest of South America)

The Middle East and Africa (Saudi Arabia, United Arab Emirates, Turkey, Egypt, South Africa, Nigeria)

Some of the Major Highlights of TOC covers:

Gene Therapy for Age-related Macular Degeneration Market Production, Revenue (Value), Price Trend by Type

Production and Market Share by Type

Revenue and Market Share by Type

Price by Type

Gene Therapy for Age-related Macular Degeneration Market Analysis by Application

Consumption and Market Share by Application

Gene Therapy for Age-related Macular Degeneration Market Production, Consumption, Export, Import by Region

Production, Consumption, Export, Import by Region

Production, Consumption, Export, Import by Country

Production, Revenue, Price and Gross Margin

Gene Therapy for Age-related Macular Degeneration Market Manufacturing Analysis

Key Raw Materials Analysis

Market Concentration Rate of Raw Materials

Manufacturing Cost Analysis

Labor Cost Analysis

Manufacturing Cost Structure Analysis

Manufacturing Process Analysis of Gene Therapy for Age-related Macular Degeneration Market

Industrial Chain, Sourcing Strategy and Downstream Buyers

Gene Therapy for Age-related Macular Degeneration Market Chain Analysis

Raw Materials Sources of Gene Therapy for Age-related Macular Degeneration Market Major Players in 2020

Downstream Buyers

Market Dynamics

Market Drivers

Restraints

Opportunities

Increased Demand in Emerging Markets

Challenges

Porters Five Forces Analysis

Gene Therapy for Age-related Macular Degeneration Market Forecast (2020-2027)

Gene Therapy for Age-related Macular Degeneration Market Production, Revenue Forecast

Gene Therapy for Age-related Macular Degeneration Market Production, Consumption, Export and Import Forecast by Region

Gene Therapy for Age-related Macular Degeneration Market Production, Revenue and Price Forecast by Type

Gene Therapy for Age-related Macular Degeneration Market Consumption Forecast by Application

For more information and discount on this report, ask your query at:https://www.reportocean.com/industry-verticals/sample-request?report_id=mai12777

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, and Asia.

Contact Us: +1 888 212 3539 (US) +91-9997112116 (Outside US)Contact Person: DavidEmail:[emailprotected]

Read the original:
Gene Therapy for Age-related Macular Degeneration Market by global COVID-19 impact analysis, industry trends, business strategies, opportunities and...

Read More...

Artificial nanoparticles are not as good as the real thing – Scientific American

June 18th, 2020 8:45 am

Credit: Robert Lisak

Exosomes are a sensational biological discovery. These minute lipid sacsamong the smallest of biological particles known as nanovesiclesare produced and then secreted by all cell types in all animal species. Bacteria produce very similar nanovesicles.

Exosomes are present in all body fluids and seem to be involved in nearly all biological processes. The main function of exosomes is to enter cells, either nearby in the tissues or systemically after transiting through the bloodstream, to deliver the genetic information that they carry. In particular, exosomes transfer microRNAs (miRNAs)small ribonucleotide polymers of about 22 bases. The extracellular miRNAs carried by exosomes can lead to alterations of DNA in the nuclei of targeted acceptor cells. The modifications to cellular DNA, in turn, alter the production of proteins and, therefore, change cell function. Exosomes are unanticipated universal nanoparticles that can mediate previously undiscovered biological processes, and alter molecular and metabolic pathways of cells and whole organisms.

These universal nanoparticles of life are likely to be of great medical importance. They might give researchers a better understanding of disease mechanisms, lead to new diagnostic tests and, perhaps most importantly, provide a means to deliver new therapies. But this will happen only if researchers study these natural entities more intensively.

Unfortunately, biomedical engineers have instead fixated on a different and less promising avenue: the development of artificial nanoparticles that imitate the function of natural exosomes for drug and small RNA delivery. Compared with naturally occurring exosomes, which have evolved an optimal composition over billions of years, engineered nanoparticles have a number of downsides. Unlike exosomeswhich can cross natural tissue barriers such as the bloodbrain barrier, can have effects for four to five days after administration and can enter the bloodstream1artificial nanoparticles cannot cross such barriers and are rapidly eliminated by mechanisms that detect foreign entities. Natural exosomes in the blood avoid physiological clearance mechanisms, but engineered nanoparticles are taken up and destroyed.

Exosome membranes are composed of unusual proportions of lipid components that give them a high surface viscosity and rigidity. This composition aids their survival in harsh conditions that kill cells. Such properties might be derived from the ancient origins of exosomes antecedent vesicles in noxious primordial seas near the beginning of biological evolutioneven before the development of bacteria.

Exosomes remarkable resistance to harsh conditions, such as the acidic and digestive-enzyme-rich environment of the stomach, means that they could be given orally as therapeutics1. Not only would this be more acceptable to and comfortable for patients, especially children, than intravenous, intraperitoneal and subcutaneous routes. But oral administration has also been shown to be a superior delivery method in mice.

Their stability and resilience are only part of what makes exosomes a natural choice for delivering genetic and anti-inflammatory molecules as therapies, both locally and systemically. They also lend themselves to therapeutic use in numerous other ways. It is likely that exosomes can be isolated from healthy individuals, and that a biologically active subpopulation can easily be enriched by a purification method called antigen or antibody affinity chromatography to promote therapy. Exosomes can also, in some instances, be used across species, without concern for immunological or genetic incompatibility, because miRNAs are often universal. Exosomes from plants might even have some medical use. And because exosomes do not contain full-length DNA, they are unlikely to cause cancer.

Exosomes also have an advantage over artificial drug carriers when it comes to targeting. Some exosomes can bind to selected antigen-specific antibody chains on their surfaces2. This gives exosomes an unrivalled ability to specifically target acceptor cells expressing particular surface antigens. Their uniquely targeted gene-altering miRNA cargo is also simple for researchers to load because activated exosomes can associate with miRNAs of choice by mere incubation3. Exosomes could therefore be used both to battle pathogens and to facilitate gene therapies for a variety of disorders.

Research indicates that exosomes might be effective therapies for diseases such as cancer, multiple sclerosis, rheumatoid arthritis, stroke, spinal-cord injury, myocardial infarction and lung fibrosis. Furthermore, investigations have begun into the use of exosome therapy for neurological conditions such as Alzheimers disease, Parkinsons disease and even autism spectrum disorder. However, much more work is needed before RNA-carrying exosomes can fulfil their therapeutic potential. One important task is to determine the nature of the surface molecules on exosomes that allow them to bind to targeting antibodies, as well as the molecular arrangements that allow them to also associate with selected therapeutic RNAs. Artificial nanoparticles do not have these capabilities. Now is the time for researchers to usher in a new era of therapeutic possibilities using RNA-delivering, natural exosome vesicles.

Philip W. Askenase is an immunologist at Yale University School of Medicine in New Haven, Connecticut.e-mail: philip.askenase@yale.edu

Here is the original post:
Artificial nanoparticles are not as good as the real thing - Scientific American

Read More...

The membrane chromatography market is estimated to grow from USD 198 million in 2020 to USD 408 million by 2025, at a CAGR of 15.5% – GlobeNewswire

June 18th, 2020 8:45 am

New York, June 18, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Membrane Chromatography Market by Product, Technique, Operation Mode, End User - Global Forecast to 2025" - https://www.reportlinker.com/p05339881/?utm_source=GNW 5% during the forecast period. The major factors driving the growth of this market are the benefits offered by membrane chromatography over conventional chromatography methods, increasing biopharmaceutical R&D, and increasing regulatory scrutiny on the cleaning validation of downstream purification processes.

The consumables segment commanded the largest share of the market in 2019.On the basis of product, the membrane chromatography market is segmented into consumables and accessories.The capsules, cassettes, and cartridges segment accounted for the largest share of the membrane chromatography consumables market in 2019.

The large share of this segment is primarily attributed to the increasing use of capsules and cartridges for purification applications in biomanufacturing, lab-scale production, and process development.

The affinity membrane chromatography segment is expected to register the highest growth in the global membrane adsorbers market during the forecast period.On the basis of technique, the membrane adsorbers market is segmented into ion exchange membrane chromatography, affinity membrane chromatography, and hydrophobic interaction membrane chromatography.The affinity membrane chromatography segment is estimated to grow at the highest CAGR during the forecast period.

The increasing use of protein A chromatography for antibody purification and immobilized metal affinity membrane chromatography for the purification of proteins are supporting the growth of this segment.

The pharmaceutical and biopharmaceutical companies segment commanded the largest share of the membrane chromatography market in 2019.Based on end user, the membrane chromatography market is segmented into pharmaceutical and biopharmaceutical companies, CROs, and academic and research institutes.In 2019, the pharmaceutical and biopharmaceutical companies segment accounted for the largest market share.

The large share of this segment is attributed to the increased R&D in pharmaceutical and biopharmaceutical companies and increased production of biologics.

The bind-elute segment is projected to register the highest growth in the global membrane adsorbers market during the forecast period.The bind-elute membrane chromatography segment is estimated to grow at the highest CAGR during the forecast period. The increasing demand for viruses in the production of attenuated vaccines and gene therapy and the development of high-performance bind-elute membrane chromatography solutions (with a higher binding capacity to capture larger targets such as adenovirus and lentivirus and virus-like particles) are the key factors driving the growth of this segment.

The Asia Pacific market is projected to register the highest growth in the global membrane chromatography market during the forecast period.The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. The growing biopharmaceutical industry, significant investments by key market players, increasing government support, and developing R&D infrastructure are the key factors driving the growth of this segment.

In-depth interviews were conducted with chief executive officers (CEOs), marketing directors, other directors, and executives from various key organizations operating in the membrane chromatography market. By Respondent Type: Supply Side (70%) and Demand Side (30%) By Designation: Managers (55%), CXOs (20%), and Executives (25%) By Region: North America (50%), Europe (20%), APAC (20%), and the RoW (10%)

The membrane chromatography market comprises major players such as Sartorius AG (Germany), Danaher Corporation (US), Merck Millipore (Germany), Thermo Fisher Scientific Inc. (US), and 3M Company (US). The study includes an in-depth competitive analysis of these key players in the membrane chromatography market, along with their company profiles, recent developments, and key market strategies.

Research Coverage:The market study covers the membrane chromatography market across various segments.It aims at estimating the market size and the growth potential of this market across different segments based on product, technique, end user, and region.

The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Key Benefits of Buying the Report:The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall membrane chromatography market and its subsegments.This report will help stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies.

The report will also help stakeholders to understand the pulse of the market and provide information on the key market drivers, restraints, opportunities, and challenges.Read the full report: https://www.reportlinker.com/p05339881/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read the original here:
The membrane chromatography market is estimated to grow from USD 198 million in 2020 to USD 408 million by 2025, at a CAGR of 15.5% - GlobeNewswire

Read More...

Genetic Modification Therapies Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By MRE – Cole…

June 18th, 2020 8:45 am

The global Genetic Modification Therapies market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Genetic Modification Therapies market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

The global Genetic Modification Therapies market is expected to exceed more than US$ 3.5 Billion by 2024 at a CAGR of 34% in the given forecast period.

Genetic modification therapies, significantly gene therapy and RNA therapy, have existed for many years, with very little clinical success. However, recent enhancements in these therapies, together with higher delivery systems, additional economical and sturdy gene expression constructs, precise polymer editing tools, have brought this industry to the forefront, and its currently poised for explosive growth within the coming back years.

Browse Full Report: https://www.marketresearchengine.com/genetic-modification-therapies-market

Because of the potentially curative nature of those medicines theres monumental potential in several applications, starting from cancer to neurology to rare diseases. Genetic modification therapies represent consecutive wave of medicines with monumental potential for treating and curing draining and high diseases. As a result of its wide scope, genetic modification therapy can play a vital role within the future world medical economy.

Continuing advances in key technologies like DNA editing, viral design and production, and gene expression, further as a pressing medical want in several serious and enervating disorders, are driving the expansion of the marketplace for genetic modification therapies. Developments in these multidisciplinary fields promise to advance the genetic modification therapies trade and build distinctive market opportunities.

The overall market is anticipated to witness important growth in opportunities for a spread of stakeholders within the returning decade. its necessary to spotlight that many technology suppliers, reaching to develop and / or support the event of gene therapies, with improved effectiveness and safety, have designed and already introduced advanced platforms for the engineering of vectors. Innovation during this domain has additionally semiconductor diode to the invention of novel molecular targets and strong the analysis pipelines of corporations targeted during this house. the potential to focus on numerous therapeutic areas is taken into account to be amongst the foremost outstanding growth drivers of this market.

Market Insights

The global Genetic Modification Therapies market is segregated on the basis of Platform Technology as Gene editing, Gene Therapies, Genetically Modified Cell Therapies, and RNA Therapies. Based on Delivery Technologies the global Genetic Modification Therapies market is segmented in AAV, Adenovirus, Lentivirus, Retrovirus, Other Viral, and Nonviral Based on End-User Industry the global Genetic Modification Therapies market is segmented in Hospitals, Diagnostics and Testing Laboratories, Academic and Research Organizations, and Others.

Based on Disease, the global Genetic Modification Therapies market is segmented in Cardiology, Oncology, Ophthalmology, Hematology, Musculoskeletal, Neurology, Rare Diseases, Other Indications.

Competitive Rivalry

4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore, Jivana Biotechnology, and others are among the major players in the global Genetic Modification Therapies market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.

The Genetic Modification Therapies Market has been segmented as below:

The Genetic Modification Therapies Market is segmented on the lines of Genetic Modification Therapies Market, By Platform Technology, Genetic Modification Therapies Market, By Delivery Technologies, Genetic Modification Therapies Market, By End-User Industry, Genetic Modification Therapies Market, By Disease, Genetic Modification Therapies Market, By Region and Genetic Modification Therapies Market, By Company.

Genetic Modification Therapies Market, By Platform Technology this market is segmented on the basis of Gene editing, Gene Therapies, Genetically Modified Cell Therapies and RNA Therapies. Genetic Modification Therapies Market, By Delivery Technologies this market is segmented on the basis of AAV, Adenovirus, Lentivirus, Retrovirus, Other Viral and Nonviral. Genetic Modification Therapies Market, By End-User Industry this market is segmented on the basis of Hospitals, Diagnostics and Testing Laboratories, Academic and Research Organizations and Others. Genetic Modification Therapies Market, By Disease this market is segmented on the basis of Cardiology, Oncology, Ophthalmology, Hematology, Musculoskeletal, Neurology, Rare Diseases and Other Indications. Genetic Modification Therapies Market, By Region this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World. Genetic Modification Therapies Market, By Company this market is segmented on the basis of 4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore and Jivana Biotechnology.

The report covers:

Global Genetic Modification Therapies market sizes from 2015 to 2024, along with CAGR for 2018-2024Market size comparison for 2017 vs 2024, with actual data for 2017, estimates for 2018 and forecast from 2019 to 2024Global Genetic Modification Therapies market trends, covering comprehensive range of consumer trends & manufacturer trendsValue chain analysis covering participants from raw material suppliers to the downstream buyer in the global Genetic Modification Therapies marketMajor market opportunities and challenges in forecast timeframe to be focusedCompetitive landscape with analysis on competition pattern, portfolio comparisons, development trends and strategic managementComprehensive company profiles of the key industry players

Report Scope:

The global Genetic Modification Therapies market report scope includes detailed study covering underlying factors influencing the industry trends.

The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.

The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Genetic Modification Therapies market share. Major industry players with significant revenue share include 4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore, Jivana Biotechnology, and others.

Reasons to Buy this Report:

Gain detailed insights on the Genetic Modification Therapies industry trendsFind complete analysis on the market statusIdentify the Genetic Modification Therapies market opportunities and growth segmentsAnalyse competitive dynamics by evaluating business segments & product portfoliosFacilitate strategy planning and industry dynamics to enhance decision making

Request Sample Report from here: https://www.marketresearchengine.com/genetic-modification-therapies-market

Table of Contents:

IntroductionResearch MethodologyExecutive SummaryMarket Overview4.1 Introduction4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.2.4 Challenges4.2 Porters Five Force AnalysisGenetic Modification Therapies Market, By Platform TechnologyGenetic Modification Therapies Market, By Delivery TechnologiesGenetic Modification Therapies Market, By End-User IndustryGenetic Modification Therapies Market, By DiseaseGenetic Modification Therapies Market, By GeographyCompetitive InsightsCompany Profiles11.1 4D Molecular Therapeutics11.1.1 Company Overview11.1.2 Product/Service Landscape11.1.3 Financial Overview11.1.4 Recent Developments11.2 Abeona Therapeutics11.2.1 Company Overview11.2.2 Product/Service Landscape11.2.3 Financial Overview11.2.4 Recent Developments11.3 Beam Therapeutics,11.3.1 Company Overview11.3.2 Product/Service Landscape11.3.3 Financial Overview11.3.4 Recent Developments11.4 Casebia Therapeutics,11.4.1 Company Overview11.4.2 Product/Service Landscape11.4.3 Financial Overview11.4.4 Recent Developments11.5 Editas Medicine,11.5.1 Company Overview11.5.2 Product/Service Landscape11.5.3 Financial Overview11.5.4 Recent Developments11.6 Fate Therapeutics,11.6.1 Company Overview11.6.2 Product/Service Landscape11.6.3 Financial Overview11.6.4 Recent Developments11.7 GE Healthcare,11.7.1 Company Overview11.7.2 Product/Service Landscape11.7.3 Financial Overview11.7.4 Recent Developments11.8 Hitachi Chemical Advanced Therapeutics,11.8.1 Company Overview11.8.2 Product/Service Landscape11.8.3 Financial Overview11.8.4 Recent Developments11.9 Immunocore,11.9.1 Company Overview11.9.2 Product/Service Landscape11.9.3 Financial Overview11.9.4 Recent Developments11.10 Jivana Biotechnology,11.10.1 Company Overview11.10.2 Product/Service Landscape11.10.3 Financial Overview11.10.4 Recent Developments

Other Related Market Research Reports:

Guar Gum Market is Forecast to Cross US$ 1.5 Billion by 2024

High Content Screening Market to Grow US$ 1.10 Billion by 2024

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Go here to read the rest:
Genetic Modification Therapies Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By MRE - Cole...

Read More...

bluebird On The Go, And Other News: The Good, Bad And Ugly Of Biopharma – Seeking Alpha

June 18th, 2020 8:45 am

bluebird on the Go with Multiple Positive Trial Data

bluebird bio (BLUE) announced data from its different trials, including Phase 1/2 clinical trial for sickle cell disease and from a Phase 3 clinical trial for transfusion-dependent beta-thalassemia patients.

Ongoing Phase 1/2 clinical trial HGB-206 aims to assess the potential of LentiGlobin in treating adolescents and adults with sickle cell disease. As on the data cutoff date, 37 patients had been treated. Group C showed promising results as all the patients included in the cohort stopped regular blood transfusions. These patients also remained transfusion-free for the time period of three months after the treatment.

Sixteen patients who were followed up for minimum six months maintained the median levels of gene therapy-derived anti-sickling hemoglobin. It also contributed to minimum 40 percent of total hemoglobin. 14 patients with previous background of acute chest syndrome (ACS) and vaso-occlusive crisis (VOC) who have been observed for a minimum time period of six months showed a 99.5 percent drop in the annualized rate of ACSs and VOCs.

Its ongoing Phase 3 clinical trials aimed to test the prospects of Zynteglo, formerly known as LentiGlobin, in treating adolescent and adult patients suffering from a range of genotypes of transfusion-dependent beta-thalassemia. Phase 3 of the Northstar-2 study involved 23 patients who were treated and observed for a median time period of 19.4 months. 89.5 percent of evaluable participants numbering 19 showed transfusion independence. Earlier, the 17 needed a median of 17.5 transfusions each year.

The Northstar-3 study involved 15 patients with genotypes of different variations. These patients were treated and then observed for a median time period of 14.4 months. 75.0% (n=6/8) reported to be transfusion independent. 84.6% (n=11/13) with a minimum of seven months' follow-up did not require a transfusion in more than seven months. Earlier, 11 of the patients needed a median of 18.5 transfusions every year.

bluebirds gene therapy involves extracting a patients stem cell and then altering it with new genetic instructions. Such altered stem cell is then infused back into the patients body. David Davidson, M.D., chief medical officer, bluebird bio, said, Vaso-occlusive crises (VOCs) are the painful, life-threatening episodes that are the primary clinical manifestation of sickle cell disease. The nearly complete elimination of VOCs that we saw in this study is impressive and demonstrates the potential of LentiGlobin for SCD as a treatment for this serious disease.

The Northstar-2 study showed three and two serious occurrences of veno-occlusive liver disease and thrombocytopenia respectively. Northstar-3 showed two serious occurrences of pyrexia. However, there was no reporting of any death, graft failure or leukemia. Zynteglo is already approved in the European Union, and the company is looking to start treating patients in Germany in the near future. It also plans to apply for the FDA approval in mid-2021.

For its Phase 1/2 trial in sickle cell anemia, an earlier report had shown significant improvement in VOCs and ACS after the gene therapy. Pursuant to these results, the company consulted with the FDA to alter the primary endpoint of the trial from improvement in hemoglobin measurements to the elimination of VOCs.

BeiGene (BGNE) announced new data from its trials aimed at assessing the potential of BTK inhibitor Brukinsa (zanubrutinib) and PD-1 inhibitor tislelizumab in treating various blood cancers. Brukinsa is a small molecule inhibitor of Brutons tyrosine kinase. It is currently being assessed as a monotherapy and in combination with other therapies of treating a wide range of B-cell malignancies.

For Phase 1/2 study of Brukinsa in patients suffering from B-cell malignancies, the overall response rate was 80 percent, while complete response rate was 15 percent. Further, the partial response rate for the trial was 65 percent. The median time to response was measured at 2.8 months. The progression-free survival rate and overall survival rate at 24 months were 59.4 percent and 83.2 percent respectively. Zanubrutinib was found to be well-tolerated in patients with R/R MZL, however, all patients experienced at least one adverse event.

The company also presented data from a Phase 2 trial of zanubrutinib with rituximab in patients suffering from R/R NHL. The trial had 41 participants, including 20 patients suffering from non-GCB DLBCL who previously received standard anthracycline rituximab-based treatment. For patients with R/R non-GCB DLBCL, the ORR was 35 percent and the CR and PR rates were 5 percent and 30 percent, respectively. For patients with R/R FL, the OR was 56.3 percent, with CR and PR at 19 percent and 38 percent, respectively.

Brukinsa is already approved in the United States for treating adult patients suffering from mantle cell lymphoma who have been given minimum one prior therapy. It was given the approval under accelerated approval pathway on the basis of its overall response rate. The drug is approved in China for treating MCL in adult patients who have received at least one prior therapy and CLL or SLL in adult patients who have received at least one prior therapy. However, the drug is not approved outside of the United States and China.

TG Therapeutics (TGTX) reported positive interim data from its Phase 1 parallel dose-escalation study of TG-1701. The drug candidate is being tested as a monotherapy and in combination with U2 for treating relapsed/refractory B-cell malignancies.

The data pertained to 82 patients suffering from the condition. Sixty-nine patients were given single agent TG-1701, out of which 25 were included in the monotherapy dose escalation cohort of the study and were given the drug candidate in 100mg to 400mg dosage once a day daily. The remaining 44 patients were included in the monotherapy dose expansion arm and were administered 200mg of the drug candidate. The TG-1701 plus U2 dose escalation portion of the study treated an additional 13 patients.

For the monotherapy dose escalation cohort with 25 patients, the drug candidate showed partial response for all the dose levels in CLL, MCL, WM and SLL. For the monotherapy dose expansion cohort, the overall response rate was recorded at 92 percent in CLL patients. MCL patients and WM patients showed 33 percent and 86 percent ORR respectively. The combination of the drug candidate with U2 showed positive clinical activity with a 77 percent ORR for all disease types. It included complete response rate in three patients. The company continues with dose escalation.

TG-1701 showed a positive preliminary safety profile for all dose levels. No patient had to discontinue the treatment, but 3 percent of the patients had to reduce the dose due to the occurrence of treatment-related adverse events. The company also provided data pertaining Phase I/Ib study aiming to assess the potential of ibrutinib in blend with umbralisib for patients with relapsed/refractory CLL or MCL.

Thanks for reading. At the Total Pharma Tracker, we do more than follow biotech news. Using our IOMachine, our team of analysts work to be ahead of the curve.

That means that when the catalyst comes that will make or break a stock, weve positioned ourselves for success. And we share that positioning and all the analysis behind it with our members.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Original post:
bluebird On The Go, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha

Read More...

Non-Viral Transfection Reagents and Systems Market, 2020-2030 – Yahoo Finance

June 18th, 2020 8:45 am

INTRODUCTION Over the last few years, the exponential growth in the pipeline of nucleic acid based therapies has led to the escalating interest of pharmaceutical industry in this domain.

New York, June 18, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Non-Viral Transfection Reagents and Systems Market, 2020-2030" - https://www.reportlinker.com/p05915358/?utm_source=GNW Presently, more than 2,000 trials evaluating different types of gene therapies are underway. Moreover, according to experts at the US FDA, around 40 new gene therapies are likely to be approved by 2022. In this context, it is worth highlighting that viral vectors are a crucial element in gene therapy development and manufacturing. Although, viral vectors have shown significant success in R&D, their applications are limited due to immunogenicity and toxicity related concerns, high development costs and the limitation on amount of genomic material that they can carry. Excessively high price tags associated with viral-based therapies, such as Zolgensma (USD 2.1 million) and Luxtruna (USD 850,000), have led to several reimbursement challenges, thereby decreasing patient access. Owing to the aforementioned concerns related to viral vectors, therapy developers are evaluating a variety of non-viral methods of gene delivery.

In the present scenario, non-viral transfection systems are not yet widely used in therapy development and clinical studies, primarily due to their relatively low efficiency compared to viruses. The applications of these methods are largely restricted to fundamental research, including protein and gene expression, and cell line development. However, there are a number of companies that have developed proprietary technologies and products to facilitate physical (electroporation, gene gun, microinjection and sonoporation), chemical (transfection reagents) and other non-viral methods of transfection (transposon based systems, piggyBac and magnetofection). We believe that, as the demand for advanced therapy medicinal products, which require genetic engineering, the opportunity for non-viral transfection system developers is also likely to grow.

SCOPE OF THE REPORTThe Non-Viral Transfection Reagents and Systems Market, 2020-2030 report features an extensive study of the various systems and technologies available for non-viral transfection, in addition to the current market landscape and future potential of product developers.

Amongst other elements, the report features: A detailed assessment of the competitive landscape of various types of non-viral transfection systems, including transfection reagents, electroporation-based transfection systems and other non-viral transfection systems, featuring product specific information, such as type of carrier used, type of molecule delivered, recommended cell type and price of the system (if available). Additionally, the chapter includes information on non-viral transfection system developers, including information on year of establishment, company size and geographical location. An insightful 2X2 representation, highlighting the competitiveness analysis of non-viral transfection system developers captured in our database, taking into consideration supplier power (based on company size) and service strength (based on strength of product portfolio, years of experience and type of molecule delivered). An analysis highlighting potential strategic partners segregated based on likelihood of entering into collaboration with non-viral transfection system developers. The analysis takes into consideration multiple relevant parameters, such as type of therapy, pipeline strength, pipeline maturity, type of vector and company size. An analysis of the big pharma players engaged in this domain, featuring a heat map based on parameters, such as type of initiative, type of therapy and target therapeutic area. An analysis of completed, ongoing and planned clinical studies related to non-viral transfection systems, featuring details on registration year, trial phase, trial status, type of sponsor, type of therapy, target therapeutic area, trial design, type of patient allocation model used, type of trial masking adopted, type of intervention, trial purpose, geographical location of trial and enrolled patient population. An in-depth analysis of close to 14,000 patents related to non-viral transfection systems that have been filed / granted since 2017, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis. A detailed publication analysis of more than 1,100 peer-reviewed, scientific articles that have been published since 2014, highlighting the key trends associated with these publications, across year of publication, focus area, type of molecule delivered, target therapeutic area, important cells and cell lines evaluated, leading players across different geographies and key journals (in terms of number of articles published in the given time period) within this domain.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity within the market. Based on several parameters, such as annual number of transfections, cost per transfection, share of non-viral systems within the transfections market and expected annual growth rate across various geographies, we have provided an informed estimate of the likely evolution of the market, in the mid to long term, for the period 2020-2030. The chapter features the likely distribution of the future opportunity across [A] non-viral transfection systems (non-viral transfection reagents, electroporation-based transfection systems and other non-viral transfection systems), [B] end-users (academic and research institutions, pharmaceutical companies and other end-users), [C] area of application (clinical application and research application) and [D] geographical regions (North America, Europe, Asia-Pacific and rest of the world).

In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the markets evolution. The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. In addition, the report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names): George Eastwood (Vice-President of Business Development, Kytopen) Claudia Andretta (Global Business Development Manager, Clinical, Polyplus-transfection)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified..

RESEARCH METHODOLOGYThe research, analysis and insights presented in this report are backed by a deep understanding of insights gathered from both secondary and primary sources. For all our projects, we conduct interviews with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include Annual reports Investor presentations SEC filings Industry databases News releases from company websites Government policy documents Industry analysts views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINESChapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the non-viral transfection systems market in the mid to long term.

Chapter 3 provides an overview of transfection and its applications, such as advanced therapy medicinal product development, gene silencing, bioproduction of therapeutic protein and stem cell engineering. It highlights different methods of transfection (such as viral and non-viral), with a brief outline of various viral vectors (AAV, adenoviral, lentiviral, retroviral and others), chemical methods (lipoplexes, polyplexes, lipoplexes and others) and physical methods (electroporation, gene gun, sonoporation, magnetofection and others) used in transfection.

Chapter 4 provides an overview of various types of non-viral transfection systems including transfection reagents, electroporation-based transfection systems and other non-viral transfection systems, featuring product specific information, such as type of carrier used, type of molecule delivered, recommended cell type and price of the system (if available). Additionally, the chapter includes information on non-viral transfection system developers, including information on year of establishment, company size and geographical location.

Chapter 5 provides a detailed competitiveness analysis of the companies offering non-viral transfection systems, taking into consideration supplier power (based on company size) and service strength (based on strength of product portfolio, years of experience and type of molecule delivered).

Chapter 6 includes detailed profiles of prominent transfection reagent developers, electroporation-based transfection system developers and other non-viral delivery system developers, featuring a brief overview of the company, its financial information (if available), recent developments and an informed future outlook.

Chapter 7 features an insightful analysis, highlighting potential strategic partners, based on likelihood of entering into collaboration with non-viral transfection system developers, taking into account several parameters, such as type of therapy, pipeline strength, pipeline maturity, company size and type of vector.

Chapter 8 highlights the activity of top ten big pharma players in this domain, featuring a heat map based on parameters, such as such as type of initiative, type of therapy and target therapeutic area.

Chapter 9 provides an analysis of completed, ongoing and planned clinical studies related to non-viral transfection systems, featuring details on registration year, trial phase, trial status, type of sponsor, type of therapy, target therapeutic area, trial design, type of patient allocation model used, type of trial masking adopted, type of intervention, trial purpose, geographical location of trial and enrolled patient population.

Chapter 10 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been filed / granted related to non-viral transfection systems, since 2017, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis.

Chapter 11 presents a detailed publication analysis of more than 1,100 peer-reviewed, scientific articles that have been published since 2014, highlighting the key trends associated with these publications, across year of publication, focus area, type of molecule delivered, target therapeutic area, important cells and cell lines evaluated, leading players across different geographies and key journals (in terms of number of articles published in the given time period) within this domain.

Chapter 12 presents a detailed market forecast, highlighting the future potential of the non-viral transfection systems market till the year 2030. The chapter features the likely distribution of the opportunity across different [A] non-viral transfection methods (non-viral transfection reagents, electroporation-based transfection systems and other non-viral transfection systems), [B] end-users (academic and research institutions, pharmaceutical companies and other end-users), [C] area of application (clinical application and research application) and [D] geographical regions (North America, Europe, Asia-Pacific and rest of the world).

Chapter 13 is a collection of executive insights of the discussions that were held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with George Eastwood (Vice-President of Business Development, Kytopen) and Claudia Andretta (Global Business Development Manager, Clinical, Polyplus-transfection).

Chapter 14 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it summarizes the various evolutionary trends that are likely to influence the future of this market.

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16 is an appendix, which contains the list of companies and organizations mentioned in the report.Read the full report: https://www.reportlinker.com/p05915358/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

View original post here:
Non-Viral Transfection Reagents and Systems Market, 2020-2030 - Yahoo Finance

Read More...

Men’s Health Month: What preventative care men should be taking – Local News 8 – LocalNews8.com

June 17th, 2020 11:50 am

Health

REXBURG, Idaho (KIFI/KIDK) - Maintaining a healthy body is important for both genders but also taking the time to bring awareness to common health issues that are more common in one encourages early detection and treatment, according to family physician at Seasons Family Medicine, Dr. Michael Packer.

"The essence of preventative medicine is that catching something early and dealing with it almost always means less pain, less trouble, less procedures than catching it later," Dr. Packer said.

There are key things Dr. Packer suggests everyone should be doing to stay healthy, "The foundational thing is active lifestyle and healthy diet."

As men get older, Dr. Packer says there are common health issues they should be actively preventing.

"Age by age, there are different things that we ought to be following when you hit your 40s and 50s we need to be doing some cancer screening like screening for prostate cancer, screening for colon cancer. The biggest risk for men is cardiovascular disease and so making sure that cholesterol is well controlled making sure they don't have diabetes, making sure their blood pressure is controlled."

According to a study done by the CDC, most preventative care visits are made by women versus men. Dr. Packer tells us this is especially concerning during the COVID-19 pandemic when many people have put off their medical care.

"A healthier person, if they get the disease is a lot better than somebody who has a lot of other health issues," Dr. Packer said.

Many doctors in the area are offering telehealth visits for those who don't feel comfortable coming in.

Idaho / Idaho Falls / Local News / News / Top Stories / Videos

Link:
Men's Health Month: What preventative care men should be taking - Local News 8 - LocalNews8.com

Read More...

Cannabinoids in medicine part 5: Treating COVID-19 – Open Access Government

June 17th, 2020 11:50 am

Following previous articles in Open Access Government where we discussed the treatment of cancer, pain, psoriasis, rheumatoid arthritis and epilepsy, this final piece focuses on the use of cannabinoids to treat COVID-19.

The coronavirus disease 2019 (COVID-19) is an infectious disease caused by SARS-CoV-2, a novel coronavirus that was first identified in Wuhan, China, in December 2019 (Smith & Mackenzie, 2020). Since then, COVID-19 has spread globally, resulting in an ongoing pandemic. In the UK alone, there were over 275,000 confirmed cases of the disease, resulting in more than 39,000 deaths as of 2nd June 2020. Worldwide, 6.37 million confirmed cases and over 377,000 deaths were reported.

COVID-19 is part of a large family of coronaviruses. Some are relatively harmless, causing only common cold-like symptoms, while others can be more severe, causing diseases such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) (World Health Organization (WHO), 2020). Following the SARS outbreak in 2002, and MERS in 2012, COVID-19 is the third significant coronavirus outbreak in the last two decades.

Coronaviruses can be transmitted through both direct (droplet and human-to-human transmission) and by indirect contact (airborne contagion and contaminating objects). The most common symptoms associated with COVID-19 include a fever, cough, shortness of breath, fatigue and loss of smell or taste (CDC, 2020). More severe symptoms, which have been associated with adults with the disease, include pneumonia, acute respiratory distress syndrome (ARDS), sepsis and septic shock (Rothan & Byrareddy, 2020) (Huang, Wang, Ren, & Zhao, 2020).

The outcome and severity of COVID-19 are associated with excess production of proinflammatory cytokines, known as a cytokine storm (Ye, Wang, & Mao, 2020). In some patients, this leads to acute respiratory distress syndrome (ARDS), and multiple organ failure (Zaim, Ching, Sankaranarayanan, & Harky, 2020). Effectively, suppressing the cytokine storm is a crucial step in preventing the deterioration of patients with COVID-19 infection, and in saving patients lives.

Cannabidiol (CBD) has the potential to attenuate the pro-inflammatory response and cytokine storm that is observed in COVID-19 patients.

CBD is a phytocannabinoid derived from the Cannabis sativa. CBD has analgesic, anti-inflammatory, antineoplastic and chemo-preventative properties (W. A, 2008), but no psychoactive activity. CBD has been shown to be effective in reducing inflammation in an animal model of acute lung disease, where CBD reduced the production of pro-inflammatory cytokines in the bronchoalveolar lavage (BAL) fluid in the lungs (Ribeiro, et al., 2015). Suppressing the release of pro-inflammatory cytokines have the potential to be used as a therapeutic treatment for patients with COVID-19.

CBD has multiple mechanisms of action, some of which have been explored when investigating the effects of CBD on lung disease, including models of ARDS, sepsis and acute lung injury. The nuclear factor NF-kB pathway is involved in proinflammatory signalling, where NF-kB activation is widely implicated in inflammatory diseases. NF-KB is a mediator of pro-inflammatory gene induction and modulates the release of pro-inflammatory cytokines (Lawrence, 2009).

The p38 mitogen-activated protein kinase (MAPK) is an intracellular protein that can initiate inflammation (Kumar, Boehm, & Lee, 2003). The activated form of p38-MAPK (phosphorylated p38-MAPK), is upregulated in response to inflammatory and stress stimuli and plays a central role in the production of pro-inflammatory cytokines (Shieven, 2005). Blocking MAPK-p38 signalling reduces activation of pro-inflammatory cytokines and phosphorylation of p38-MAPK. CBD inhibits phosphorylated p38-MAPK, which leads to decreased production of NKkB and AP-1 (both inflammatory transcription factors) resulting in reduced inflammation (Silva, et al., 2019).

MicroRNA (miRNA) are small non-coding RNA that regulate a wide range of genes. Alternations in their expression are associated with immune responses, inflammatory signalling pathways and pathogenesis of lung diseases, such as ARDS and acute lung disease. Mi-146a is a negative regulator of inflammation, leading to the reduction of NF-KB transcriptional activity. However, mi-146a has shown to be upregulated during immune activation through increased NF-KB activity (Taganov, Boldin, Chang, & Baltimore, 2006). In one study, CBD reduced the activity of NF-KB signalling, which downregulated mi-146a expression (Kozela, et al., 2010) and decreased the release of pro-inflammatory cytokines (IL-6 and IL-1) (Juknat, Gao, Coppola, Vogel, & Kozela, 2019). This provides evidence that CBD has anti-inflammatory effects that are mediated via the NF-KB signalling pathway.

CBD also acts as an antagonist for the G-coupled protein receptor, GRP55 (Ryberg E, et al., 2007). GPR55 signalling can modulate certain pro-inflammatory cytokines The role of GPR55 on the immune response was investigated in an animal model of sepsis. The inhibition of GPR55 using CBD-related antagonists decreased the release of pro-inflammatory cytokines and reduced inflammation (Ahou, Yang, & Lehmann, 2018). GPR55 inhibition may, therefore, be a novel target for attenuating hyper-inflammation in sepsis and a potential target to treat COVID-19.

There is one ongoing clinical trial investigating the effects of CBD on COVID-19. The study, currently in proof-of-concept (POC) stage, is investigating the use of CBD in combination with steroids in a small cohort of 10 COVID-19 patients at Rabin Medical Center, Israel (Stero Biotechs, Ltd, 2020).

Within the last 20 years, we have seen three deadly coronaviruses and can expect to see more in the future. Suppressing release of pro-inflammatory cytokines by CBD provides a potentially new therapeutic approach in the treatment of COVID-19. There is limited research into CBD and COVID-19 during this current pandemic, however, there is evidence that demonstrates that CBD can reduce the cytokine storm observed in the severe symptoms of the virus. The limited research to date shows that the use of CBD to treat ARDS caused by COVID-19 and other diseases and infectious agents is a promising avenue that warrants further investigation.

References

Ahou, J., Yang, H., & Lehmann, C. (2018). Inhibition of GPR 55 improves dysregulated immune response in experimental sepsis. . 1-9.

CDC. (2020, April 28). Coronavirus Disease 2019. Retrieved May 28, 2020, from Centers for Disease Control and Prevention: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html

Huang, C., Wang, L., Ren, L., & Zhao, H. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. 395(10223), 497-506.

Juknat, A., Gao, F., Coppola, G., Vogel, Z., & Kozela, E. (2019). miRNA expression profiles and molecular networks in resting and LPS-activated BV-2 microgliaEffect of cannabinoids. 14(2).

Kozela, E., Pietr, M., Juknat, A., Rimmerman, N., Levy, R., & Vogel, Z. (2010). Cannabinoids 9-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-B and interferon-/STAT proinflammatory pathways in BV-2 microglial cells. 285(3), 1616-26.

Kumar, S., Boehm, J., & Lee, J. (2003). p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. 2(9), 716-26.

Lawrence, T. (2009). The Nuclear Factor NF-B Pathway in Inflammation. 1(6).

Ribeiro, A., Almeida, V. I., Costola-de-Souza, C., Ferraz-de-Paula, V., Pinheiro, M. L., Vitoretti, L. B., . . . Palermo-Neto, J. (2015). Cannabidiol improves lung function and inflammation in mice submitted to LPS-induced acute lung injury. 37(1), 35-41.

Rothan, H., & Byrareddy, S. (2020). The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. 109.

Ryberg E, L. N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol, 152(7), 1092-101.

Shieven, G. (2005). The biology of p38 kinase: a central role in inflammation. 5(10), 921-928.

Silva, R. L., Silveira, G. T., Wanderlei, C. W., Cecilio, N. T., Maganin, A., Franchin, M., . . . Cunha, T. M. (2019). DMH-CBD, a cannabidiol analog with reduced cytotoxicity, inhibits TNF production by targeting NF-kB activity dependent on A2A receptor. 368, 63-71.

Smith, D., & Mackenzie, J. (2020). COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we dont.

Stero Biotechs, Ltd. (2020). Stero Biotechs Announce an IP Protected Clinical Trial for COVID-19 Patients Using a CBD-Steroid Treatment. Retrieved from prnewswire: https://www.prnewswire.com/news-releases/stero-biotechs-announce-an-ip-protected-clinical-trial-for-covid-19-patients-using-a-cbd-steroid-treatment-301043465.html

Taganov, K., Boldin, M., Chang, K., & Baltimore, D. (2006). NF-kappaB-dependant induction of microRNA miR-146, an inhibitor to signalling proteins of innate immune responses. 103(33), 12481-6.

World Health Organisation (WHO). (2020, January 14). WHO Statement regarding cluster of pneumonia cases in Wuhan, China 2020. Retrieved May 29, 2020, from https://www.who.int/china/news/detail/09-01-2020-who-statement-regarding-cluster-of-pneumonia-cases-in-wuhan-china

Ye, Q., Wang, B., & Mao, J. (2020). The Pathogenesis and Treatment of the `Cytokine Storm in COVID-19. 80(6), 607-613.

Zaim, S., Ching, J., Sankaranarayanan, V., & Harky, A. (2020). COVID-19 and Multi-Organ Response. 100618.

Please note: This is a commercial profile

Chloe Morris

Intern

Editor's Recommended Articles

Excerpt from:
Cannabinoids in medicine part 5: Treating COVID-19 - Open Access Government

Read More...

Healthy Actions: Heres relief if your allergies are flaring up – Akron Beacon Journal

June 17th, 2020 11:50 am

Are your allergies particularly bad this season?

I thought this would be a great and timely issue to bring back my Healthy Actions column, a monthly chat with a local medical expert. I had to pause the columns during the height of coronavirus coverage.

My expert is Dr. Matthew Mivsek, a family medicine doctor with Unity Health Networks Hudson office.

Also check out an accompanying video with Mivsek, where we answer some reader questions.

Q: Typically, when is allergy season?

A: Tree pollination is early spring, grass pollination is late spring and summer and ragweed is late summer and early fall.

Q: Is this season worse and why?

A: Yes, there are quite a few patients coming into the office and calling the office with allergy symptoms, more so than usual this year. The likely reason is the unseasonal weather early in the year, both with warmer-than-usual temperatures early on and an unexpected snowstorm in May. The amount of precipitation has increased pollination and overall pollen counts.

The fluctuations of the temperatures led to both tree and grass pollens starting to come at the same time, which has really sent a lot of individuals allergies into overdrive.

A useful app to track the potential to aggravate allergy symptoms when spending time outside and the overall pollen counts is Weather.com. It will show breakdowns of tree pollen, grass pollen and ragweed pollen. If you know which type of pollen you are most allergic to, you can try to avoid days when the specific counts are higher.

Q: Some people say this is the worst season ever and others say theyre doing OK or had some mild issues a few weeks ago. Why?

A: What everyone is allergic to is different. Ive had people saying the same thing. It does vary from year to year and unless you know exactly what youre allergic to, its hard to say.

Q: Could stay-at-home orders keeping us inside have helped with allergies?

A: Thats a reasonable theory. Generally, staying inside in air conditioning or with the windows closed helps with allergies.

Q: Does the wind or rain affect allergies?

A: Wind can definitely make allergies worse by circulating pollen in the air. Ive heard that rain can make things worse. It may not be that day, but a few days later with the humidity. Sometimes also when the raindrops fall, theyre throwing pollen in the air.

Q: How can I tell if this is allergies, a cold, the flu or COVID-19?

A: The most important symptoms to be aware of regarding COVID-19 are fever (over 100.4 degrees Fahrenheit), cough and shortness of breath.

Allergies typically present with runny nose or nasal congestion, itchy, watery eyes and scratchy throat, predominantly. A cough is usually caused by post-nasal drainage in the setting of allergies that are not controlled.

A cold/flu/coronavirus symptom presentation can be similar, so I can understand the concern regarding this matter. A major difference between allergies and cold, flu, coronavirus is the presence of a fever.

Q: So what over-the-counter relief is there?

A: There are several options. In the category of oral antihistamines or pills, the least potent are Claritin (generic name loratadine) and Allegra (fexofenadine), moderately potent are Zyrtec (cetirizine) and Xyzal (levocetirizine) and most potent is Benadryl (diphenhydramine), but Benedryl, that does make you pretty tired and make it difficult to function throughout the day.

For nasal sprays, there are steroid nasal sprays such as Flonase, Nasacort and Rhinocort that are going to be most effective; antihistamine nasal sprays such as Astelin and saline nasal sprays such as Simply Saline and Ocean mist.

Be sure to use the nasal spray properly. Lean slightly forward and point the spray in your nose toward the outer corner of your eye. Lightly sniff. If you sniff too much and can taste the spray, it wasnt used correctly and has gone down your throat instead of into your sinuses.

For eyedrops, there are antihistamine ones, such as Zaditor, Pataday, Naphcon and Alaway.

Q: Is it preference to take a pill versus nasal spray?

A: Yes, rather than use an oral medication that goes throughout the body and can have potential side effects, if you want to directly treat the problem, you can use a nasal spray.

Q: Is it better to do something preventive and take allergy medications before the season starts instead of waiting for an attack?

A: There certainly is benefit to practicing preventive medicine in all aspects of medication, and preventative measures to alleviate allergy symptoms is no different. If you know that your allergy symptoms are the worst in the spring, beginning to take an oral antihistamine toward the end of winter can help to alleviate symptoms moving through peak allergy seasons.

Q: Is it safe to layer other medications on during a flare-up?

A: Yes, its OK to layer treatments. Taking an oral antihistamine can be paired with any nasal spray and eyedrops. You want to be careful about the decongestant part, or "D" portion of a pill, especially for someone with high blood pressure because it can elevate blood pressure. Those with high blood pressure should take Coricidin HBP.

Q: When should I call or ask a doctor for a prescription instead of trying over-the-counter remedies?

A: If youve maxed out therapies over the counter or youre uncomfortable with what youre layering, call for an appointment or telehealth appointment. You can also ask the pharmacist at the store.

Q: What about shots?

A: Thats usually done by an allergist through a referral. Before allergy shots or immunotherapy, they would do a prick test to find out which allergen is causing the response.

Q: Can wearing a mask help?

A: A mask certainly wont hurt to protect against allergens and can help with airborne pollen, just like viruses. Cloth masks are going to be the least effective, followed by surgical masks and health-grade N-95 masks. We havent necessarily used masks for treatment of allergies, but they can help, especially for those who may want to wear masks when theyre mowing the grass or doing yard work.

Beacon Journal consumer columnist and medical reporter Betty Lin-Fisher can be reached at 330-996-3724 or blinfisher@thebeaconjournal.com. Follow her @blinfisherABJ on Twitter or http://www.facebook.com/BettyLinFisherABJ and see all her stories at http://www.beaconjournal.com/topics/linfisher

Here is the original post:
Healthy Actions: Heres relief if your allergies are flaring up - Akron Beacon Journal

Read More...

June 17 Face of the Day: Dr. Emily Lange – The Daily Nonpareil

June 17th, 2020 11:50 am

Dr. Emily Lange has been an OB-GYN physician for eight years. She is currently in her fifth year at Methodist Physicians Clinic Womens Services, at Methodist Jennie Edmundson Hospital.

Lange and her husband, Arnie, have been married for eight years and have four children Anthony (6), Lucia (5), Isaac (3) and Claudia (1).

In her free time, Dr. Lange enjoys spending time outdoors with her children, meeting with her book club and participating in a womens Bible study fellowship group.

Lange also belongs to Global Partners in Hope a nonprofit organization that aims to address the tangible needs of people in communities across the globe by providing health care, clean water, sustainable energy, leadership courses and many other services.

As a physician, Lange feels very privileged that coming to work each day allows her to provide quality services to her patients.

Sometimes you see great outcomes in a finite time span such handing a healthy baby to a healthy mom, other times it is more subtle and long term such as providing education during a well woman exam about vaccines and helping individuals navigate their own healthcare goals, Lange said. I approach medicine as a partnership between me and my patients, their success is my reward.

Our Womens Center provides full spectrum gynecologic and obstetrical care. I enjoy working with women at all stages of their lives.

Much of clinic time is spent providing preventative care and education to address specific questions women have. This allows a relationship with patients to develop that is very rewarding as

I walk through many life changing events with them.

Lange continued: I love delivering babies and seeing families grow. I love the community at Jennie Edmundson. I have the best co-workers in clinic and the best nurses in the hospital.

I have delivered 3 of my children at Jennie and have been very impressed with the care from a patient standpoint as well.

We are excited to be expanding the scope of womens services to Council Bluffs and western Iowa meeting your health care needs closer to home.

Stay up to date on Jennie Edmundsons womens services renovation projects by going online to http://www.jehfoundation.org.

More:
June 17 Face of the Day: Dr. Emily Lange - The Daily Nonpareil

Read More...

Another benefit of volunteer work? Science says it can help you live longer – Health24

June 17th, 2020 11:50 am

08:45 14/06/2020 Gabi Zietsman

Volunteering isnt just good for the soul it can also increase your lifespan.

A study by the University of Michigans Institute for Social Research published in the American Journal of Preventative Medicine analysed data from comprehensive US research involving adults over the age of 50 to see if theres any correlation between volunteering and physical health, health behaviours and psychosocial wellbeing.

READ: Even a little activity keeps ageing brains from shrinking

They chose 34 indicators that signify what it means to age well how it affects things like life satisfaction, optimism, physical activity, depression and chronic conditions.

With over 12 000 participants over the span of four years, they found that those who volunteered for more than 100 hours a year about 2 hours a week had a 44% reduced mortality risk, a 17% reduced risk of mobility issues and 12% increased physical activity.

'A means to stay young'

The volunteering heroes were also less hopeless, had more of a purpose in life and felt less lonely. They were also 29% less likely not to be in regular contact with their friends.

However, the study did not find volunteering to have any impact on chronic diseases like cancer, diabetes and arthritis, certain behaviours like drinking and smoking, and other indicators like depression and connection with family.

ALSO SEE: Worried about ageing? Scientists discover 4 distinct ageing patterns

This contradicts earlier studies, although the researchers noted that it could be due to the studys missing "cause of death" statistics of participants.

Previous studies on health and volunteering also tended to be limited in sample size and skewed towards younger subjects.

It concludes that volunteering could prevent a decline in quality in life as we get older, help the psyche and make us more resilient to stress factors.

The art of helping in our communities is also something that physicians could potentially prescribe to older patients who are willing and able as a means to "stay young".

However, during the Covid-19 pandemic, those that fall in the high-risk age category need to be careful with activities outside their homes including helping their fellow humans.

Image credit: Getty Images

Excerpt from:
Another benefit of volunteer work? Science says it can help you live longer - Health24

Read More...

Dale Okorodudu, MD founder of DiverseMedicine Inc. and the Black Men In White Coats Video Series addresses healthcare disparities in this new pandemic…

June 17th, 2020 11:50 am

Dale Okorodudu, MD founder of DiverseMedicine Inc. and the Black Men In White Coats Video Series addresses healthcare disparities in this new pandemic world

Dale Okorodudu

Dale Okorodudu, MD, the founder of DiverseMedicine Inc. and the Black Men In White Coats is driven by a desire to educate our community on the short and long term impact of neglecting our health and what that does to the solo and the community at large.

Astrophysicist, cosmologist, planetary scientist, author, and science communicator, Neil deGrasse Tyson said Not only are we in the Universe, but the Universe is also in us. I dont know of any deeper spiritual feeling than what that brings upon me.

In the May 14th issue of the Los Angeles Times in an article entitled Some creators of color fear coronavirus will be a major setback in TVs diversity push, written by staff writer Greg Braxton, creators such as ABCs black-ish Kenya Barris, Gloria Calderon Kellett, co-creator and showrunner of Netflixs One Day at a Time, and John Ridley, creator of ABCs American Crime and an Oscar winner for 12 Years a Slave, expressed their concerns for the long term impact of the pandemic on people of color in the entertainment industry. Here are the facts, the virus is particularly lethal for Black and Latino segments of the population. This situationhas prompted heightened concerns among some of TVs top talents about their creative and personal futures.

When I shared this link with Dale Okorodudu, MD, via email his response was Wow. Thats the exact reason were pushing to get this done now. Perhaps some doors will open up and we can get our message out.

Doctor Okorodudu understands the uncomfortable reality about the virus and how its been particularly lethal for the African-American and Latino population. Data across the board is calculating that those of us under 50 are dying of the coronavirus at significantly greater rates than other groups, including whites.

In New York, we are at twice the rate according to preliminary data released on the date of filing. This alarming news isnt new for Dr. Okorodudu. The facts are helping to drive his initiative harder.

But Dr. Dale Okorodudu knew all of this and as the founder of DiverseMedicine Inc. and the Black Men In White Coats Video Series knowing whats ahead is one of the key reasons that hes passionate about health. Our health in particular.

Dr. Okorodudu was raised in League City, Texas (just outside of Houston), and completed both his undergraduate and medical training at the University of Missouri. He relocated to Durham, North Carolina where he completed his Internal Medicine residency training at Duke University Medical Center.

After training, Dr. Okorodudu returned to Texas and completed his Pulmonary & Critical Care Fellowship at UT Southwestern Medical Center. His clinical practice is at the Dallas VA Medical Center. Dr. Okorodudu has a passion for addressing healthcare disparities which he has done via promoting diversity in the medical workforce. Outside of medicine, he enjoys spending time with his wife, 3 children, and church family.

A white coat is a symbol and not just a garment to Dr. Okorodudu; it carries weight, especially when its on the shoulders of a black man. As a pulmonary and critical care physician, who specializes in treating lung ailments, Dr. Okorodudu has been smashing societys stereotype of what a doctor looks like ever since he started as an undergrad and continues to move forward with renewed vigor.

Here is what Dale Okorodudu, MD founder of DiverseMedicine Inc. and the Black Men In White Coats Video Series and the author of the new childrens book series called Doc to Dochad to share about why we need more Black men in the medical field.

LOS ANGELES SENTINEL: Dr. Dale Okorodudu why did you start Black Men in White Coats (BMIWC)?

DALE OKORODUDU, MD: It is an organization that I built to foster diversity in medicine through mentorship and motivation. It is my mission.

LAS: But why? Is there a shortage of Black men in the medical profession?

DO: Yes, there is. There is only around 2 percent of medical school applicants in the United States are Black men and the number of Black males applying to medical school is declining despite rising rates in other fields of study.

LAS: Why do you think this is happening?

DO: The biggest thing is the lack of role models. A lack of mentors in the field, individuals that look like them. We have a lot of young Black men who have so much potential but they dont see people like them in the medical field. You gravitate toward whats like you and whats around you.

LAS: So its safe to say thats one of the inspirations behind creating and running Black Men In White Coats Video series and books, as well?

DO: Exactly. In exposing young black children to the idea that they could be doctors, leading by example, is paramount. Black young men need to see themselves as the men in white coats and know the coat would fit.

LAS: I am feeling you, Doctor. See it. Believe it. Become it.

DO: Exactly.

LAS: Youve written a childrens book series called Doc to Doc, why?

DO: My goal in doing this is to provide exposure to the medical field to kids of all ages and all backgrounds. Kids learn in different ways. There are all kinds of ways to reach them. Some kids watch a lot of television. Others listen to music. My older son listens to music now. Some of them love books. For those kids that do the love the books [I thought] if I can give them little kids that look like them [Black kids] that want to do things in medicine that might catch their eye.

LAS: Well it caught mine and it caught others, so bravo Doctor.

DO: Thank you. And for those that dont love the books, if I give them something that looks like them that is colorful and fun, they might begin loving and reading books. I wanted to make them fun books. I have two little kids, two little Black boys, and a little Black daughter.

LAS: I love it. Three kids. Gosh. They must keep you on your toes.

DO: (laughing) They do and they are the inspiration for the Doc to Doc series. My kids like it so I knew other kids would like [the books] it.

LAS: Genius. You have built-in marketing and focus group right inside your home. Hey, an idea just popped into my head. Have you ever thought of pitching this as an animated series for one of the streaming platforms?

DO: I would love to. Its a goal.

LAS: What are you working on right now?

DO: We are working on making a feature-length documentary on Black Men In White Coats.

LAS: Thats amazing news?

DO: Thank you. The goal is to pitch this to one of the streaming platforms.

LAS: Its so important to get your message out. You have the expertise and purpose. Now lets push into the pandemic. Thoughts?

DO: I have a lot of thoughts. I will begin with whats happening in the African-American communities and thats one of the reasons that I wrote the Doc to Doc children book series. I just put out a book in the series that concentrates on viruses.

LAS: Smart.

DO: Well, my wife suggested it because of everything thats going on right now so the kids understand whats going on. It helps to make sense of whats happening. Talking about why you should wear a mask. Why you should wash your hands. My kids are asking me about it and now its in the book as part of the growing Doc to Doc children book series. This is for kids and also informative for the parents.

LAS: Is there another part of this as well?

DO: There is and I keep going back to this. Its very important. I want to make health care fun for people. To make health care less intimidating for people. No one wants to be told that they are sick. No one wants those crazy medical bills. A lot of people fear the health care system.

LAS: And for good reason. But why are you so passionate to make us feel comfortable?

DO: Thats a great question. If more people become knowledgeable then we can move into preventive care so things wont get us bad on the back in.

LAS: So. Things. Dont Get. Us. Bad. On. The. Back. In. Got it. Amen.

DO: Right now, one of the books that I want to write is Doc to Doc on diabetes.

LAS: Dr. Dale, please write that book. Its needed for sure.

DO: This disease is impacting us and I want our community to engage with the health care community about conditions that impact us. I want the kids to understand so they begin living a different kind of lifestyle so they wont get diabetes or get caught up in the same health problems that their parents are caught up in. We must get them at an early age.

LAS: Dale Okorodudu, MD founder of DiverseMedicine Inc. and the Black Men In White Coats Video Series you are doing Gods work. Can you share some information about the feature-length documentary series on Black Men In White Coats?

DO: Weve completed the project and now in post-production. Its about the lack of Black men in medicine. A year ago we did a Kickstarter campaign (https://www.kickstarter.com/projects/drdale/black-men-in-white-coats-the-film). When we started the campaign a lot of people tried to discourage me because with Kickstarter if you dont raise all of the money you dont get a dime. My goal was 100,000 (one hundred thousand) and a lot of people, a lot, thought I was crazy. We raised it. That was validation that people want this. People understand what we are talking about. People understand the struggle. Only about 2 percent of U.S. physicians are Black and the number of Black male applicants to medical school has not been growing. We need to convince more Black boys to pursue careers in the field. In the feature length documentary, we dive into why Black men are not in the medical profession and the implications. I get too excited about this new project. Now people are talking about the pandemic and how Black and Brown people are dying at higher rates than Whites. People in my field we understand why. Like its like duh.

LAS: So this pandemic impact on people of color isnt new information for those in the medical community?

DO: No. Weve been talking about his for years. Thats just one of the reasons that we need diversity in medicine. These things come to light when other people become infected by it. We need to concentrate on preventative medicine. We need to focus on the front end.

This interview has been edited for length and clarity.

Dale@DiverseMedicine.com http://www.DiverseMedicine.com Click Below to Check Out My Amazon Bestselling Books! https://doctordalemd.com/product/how-to-raise-a-doctor-book-bundle-50/

Here is the original post:
Dale Okorodudu, MD founder of DiverseMedicine Inc. and the Black Men In White Coats Video Series addresses healthcare disparities in this new pandemic...

Read More...

2 More Deaths at NBPA Decks After Suicide Issue on Back Burner Due to the Pandemic – New Brunswick Today

June 17th, 2020 11:50 am

NEW BRUNSWICK, NJA Highland Park psychologist, age 66, died by falling from a New Brunswick parking deck on the morning of Sunday, June 7.

Her death is the ninth suicide involving one of New Brunswicks parking decks in six years, and the second to take place this year.

Reliable sources told New Brunswick Today that another similar tragedy has occurred since June 7, the second in one week. Police have not yet responded to a request for information about the incident.

New Brunswick Today reported on the eighth death in March and detailed steps that the New Brunswick Parking Authority (NBPA) could take to prevent further deaths.

Although NBPA officials previously informed New Brunswick Todays editor of potential plans to implement physical preventative barriers on one of their parking decks, those plans to prevent suicides have been put on the back burner due to the pandemic, according to the NBPAs executive director, Mitchell Karon.

The NBPA recently installed gates on some elevator doors at the topmost floors and stairwells of parking decks in response to the most recent suicides.

David Minchello, general legal counsel for the NBPA, confirmed during the April 27 NBPA Board of Commissioners meeting that he received a copy of New Brunswick Todays previous article on the issue of New Brunswicks suicides and has distributed copies to the board.

Acknowledging the seriousness of this mental health crisis, the NBPA considers the safety of our patrons in our facilities a priority, Harry S. Delgado, Director of Operations and Security for NBPA, wrote in an email to NBT reporters.

We are committed to mitigation, Delgado continued.

We have safety measures in place such as physical tours of all our twelve facilities by our Parking Services Department, the use of video analytics and other technologies coordinated to help deter these types of incidents.

While NBTs reporter investigated a parking deck facility, three security personnel approached her with compassionate concern during her time there. They eventually asked her to leave despite learning that she is a reporter. One worker explained to her that, given the recent deaths, they are being especially diligent and mindful when they notice any questionable behavior.

Kathleen Cohen, a fellow of Sports Medicine with Rutgers Robert Wood Johnson Medical School, witnessed the aftermath of the victims fall.

I was just walking when I heard what I thought was a car accident, Cohen said.

At first, I ran towards her to try to help and see what I could do but then I realized that there was nothing that I could do or that anyone could do.

Having that all happen in real time meant that I had no time to prepare myself. There was no way to protect myself from that while I was trying to understand what happened.

Police officers who responded to the incident were really compassionate, according to Cohen.

They werent judgmental.

Cohen and other witnesses were shocked and saddened by the death; officers and other witnesses, similarly to Cohen, wished they had been able to help the victim prior to her fall.

She was a block away from a very good hospital emergency room, Cohen said.

They wouldve been able to help her immediately.

Nobody saw her before she jumped or going up the floors. No one could have talked her out of that.

I dont feel responsible, but there is part of me that thinks What if I had seen her sooner? Cohen asks.

Two years prior, Susan Higgins worked as an ER nurse at New Brunswicks Robert Wood Johnson (RWJ) Hospital, where the stressors in her life snowballed and drove her into a state of despair.

I was already in a place of hopelessness, feeling that nothing mattered, and that everything in my life was pointless, Susan said.

It was a busy day. I had my patient load, but I couldnt concentrate even though I tried to stay focused.

As I was getting more depressed, I was already thinking of ways to kill myself if I really would. For whatever reason, I already felt that using the parking deck would have been the easiest thing.

Higgins admits there were several warning signs in her emotional state and behavior that she couldnt see before she reached the dark place of considering the end to her own life.

It wasnt that one or two things happened, Higgins said.

There were months, even years, of accumulated stress in work and my life.

I felt like no matter what I did, it didnt matter or how hard I worked didnt matter.

Though clinical depression is a relatively common mental illness, part of its complexity is due to its wide range of etiologies.

In Higginss case, she explained that factors in her personal life, the pervasive punitive culture in healthcare professions, and biological imbalances influenced her depression.

Theres an attitude in healthcare, especially in emergency medicine, where they say, you need to deal with this. If you cant handle it alone, youre weak. Youre not cut out for this. You cant do this anymore,' Higgins said.

Cohen also said there is a stigma among the barriers preventing healthcare workers from coming forward about their personal struggles with mental illness.

In the medical field, it is almost adaptive to see doctors and nurses as invincible, Cohen said.

They are expected to give everything they have to their profession and their patients and work overtime. Then its discouraged for them to say, Im struggling, or to disclose a psychiatric illness, even when they need support.

Particularly in health care, you need support and you cant do these things alone, Higgins said.

When you have a punitive system, where people get in trouble for mistakes, people are going to hide their mistakes. That snowballs into a culture without growth or learning and with fear The ones who suffer are the patients and healthcare workers.

A spokesperson for RWJUH has not responded to questions sent by a NBT reporter about what mental health services are available to their staff.

Alongside the strife in her work life, her clinical depression actively fought to perpetuate harmful, self-blaming perspectives.

Depression thrives in isolation, Higgins said.

The depression lies to you. It tries to convince you that youre the cause of all the problems.

Calling victims of suicide selfish misses the point.

People who die by suicide think the people who love them would be better off if theyre gone.

Susan Higgins, however, did not die that day.

She remembers January 26, 2018, as the day her life changed for the better.

Thats the day I finally reached out for help, Higgins said.

Instead of ending her life, she stopped the physicians assistant of her primary doctor, who was also working at RWJ that day.

You have to help me, She told him. I need help.

The physicians assistant connected Higgins with her primary care doctor, who reacted compassionately and responsibly by admitting her to another hospitals ER for emergency treatment.

My primary doctor saved my life that day, Higgins said.

Although getting help for her mental health was not a straightforward process, Higgins treatment has helped her build a reliable support system with a multitude of coping tools such as one-on-one counseling, group therapy, medications like antidepressants, guided meditation and more.

Therapy is kind of like an oil change, Higgins explains.

Even when I have a great support system, its still helpful for me to go back when I feel that I need it and touch base with a professional.

A good therapist does more than listen.

A therapist is going to be there to help you differentiate between what is constructive and what is helpful and what beliefs may be harmful to you.

Higgins has found medication to be especially helpful, although she was resistant at first to taking antidepressants.

I didnt want to go on antidepressants for a long time, she said. I assumed that I just needed therapy.

But when I got to a point where things were actually pretty good in my life, I still felt really depressed.

I had to try different medications and it isnt as simple as going on a pill. Sometimes you need to make changes.

Despite her complicated journey to recovery, her treatment has enabled her to better cope with challenges in her life.

The last few months managing an ER in NYC have been very stressful, but I havent been depressed, Higgins said. I certainly havent been to a point of considering killing myself.

Im happy that I got help.

Both Higgins and Cohen compared mental illnesses like depression to chronic physical illnesses like diabetes that need ongoing treatment and help.

If someone is diabetic, and they start to recognize their symptoms of low blood sugar, they know what to do. They know what steps to take to get their blood sugar back up. Then they check their blood sugar and go from there, Higgins said.

You dont have to wait until youre in a diabetic shock to get help.

Depression is a disease, and part of treatment is recognizing when you need help and taking those steps before its too late.

I dont distinguish between physical disease and mental disease as much as others tend to, because I understand that it is a physical problem, Cohen said.

In order to prevent suicides at their parking facilities, the NBPA has taken some steps in the past, as previously reported by New Brunswick Today.

Previously implemented plans include perimeter alarms on one of their eight parking decks and signage that raises awareness for the New Jersey Hopeline.

However, there is little evidence to suggest that perimeter alarms are effective as a method of suicide prevention.

Signage for suicide hotlines also do not tend to work as effective means of suicide prevention on their own.

Individuals who intend to die by suicide often do not bring their phones with them. Elizabeth Johnsen, a victim of suicide who died after falling from a New Brunswick parking deck on June 5, 2014, did not bring her phone with her.

Theres really not good evidence that signs matter all that much, Kim Kane, a suicide prevention specialist who worked to improve parking facilities in Boise, Idaho, said in a previous NBT interview.

To think you can talk someone out of suicidality with the help signs may be overly optimistic, Kathleen Cohen said.

Maybe [the reliance on signs] misunderstands the actual nature of the suicidal condition.

If somebody is suffering that much that they think that the only answer is suicide, you cant always expect them to be able to ask for help in that moment like making a phone call.

Its harder to reach that person when theyve already made up their mind, Susan Higgins said.

Barriers, while being the most expensive and intrusive method of preventing suicide, are also the only method proven to prevent deaths.

Once you put barriers up, suicides typically go to zero, Kane explained.

Means restriction is actually one of the very few things we know that actually reduces suicide rates.

Means restriction is known to be effective, Cohen said.If you can, why would you not?

Although Cohen doubts that the NBPA holds meetings to discuss their moral duty to the public, they do have fiscal and liability concerns which should make the suicides on their parking facilities a major concern.

It is both morally and financially impractical for them to allow this to continue, Cohen said.

Why dont they add fencing where you literally cant fall from the building or the parking deck? Higgins asks of the NBPA.

How much could a chain link fence cost?

If you prevent the means, you give that person a second chance, Cohen said.

When asked about plans for physical barriers, Security Director Delgado explained that NBPA has restricted pedestrian access to many areas in our facilities to authorized personnel only by installing scissor gates and other physical barriers.

Those barriers have been installed on some of the elevator entrances of the topmost floors and the stairwells of their parking facilities.

Structural modifications to our facilities are currently being considered, Delgado said.

Delgado recognizes the issue as a mental health crisis exasperated by a public health crisis.

The NBPA is committed to do anything it can in [their] efforts to mitigate these tragic incidents, Delgado said.

If someone exhibits any warning signs of suicide, they should not be left alone.

They should be taken to any medical facility for emergency treatment.

Warning signs to watch out for:

Steps you can take to help:

I know that its really hard to help yourself, but its not shameful to get help. Higgins said. Its not weakness. It does not mean that you arent able to cope with something.

It is the same as if you have a broken leg or a chronic medical illness. Sometimes you need outside help, and it is OK to ask for help.

Kristin is a graduate of Rutgers University and a reporter with New Brunswick Today

Mohsin is a third-year Rutgers student whose passion for local activism, artistic expression, and organizational leadership is only matched by his desire to bring intriguing, relevant stories to the New Brunswick community.

Read this article:
2 More Deaths at NBPA Decks After Suicide Issue on Back Burner Due to the Pandemic - New Brunswick Today

Read More...

Face masks help to limit the spread of the coronavirus, research shows – Business Insider – Business Insider

June 17th, 2020 11:50 am

Partisanship in American politics has weaponized the face mask while people continue to fall sick and die of the coronavirus.

But a growing body of research shows that wearing face coverings in public can limit the spread of the highly contagious disease, which has infected more than 2 million people in the United States and killed 115,251 as of Saturday, based on data from Johns Hopkins University.

A review and meta-analysis funded by the World Health Organization and published in The Lancet, a peer-reviewed medical journal, examined data from 172 studies from 16 countries and six continents.

Without a mask, the risk of transmitting COVID-19 is 17.4%. With an N95 respirator or face mask, that number drops to 3.1%.

"Our findings continued to support the ideas not only that masks in general are associated with a large reduction in risk of infection from SARS-CoV-2, SARS-CoV, and MERS-CoV but also that N95 or similar respirators might be associated with a larger degree of protection from viral infection than disposable medical masks or reusable multilayer (1216-layer) cotton masks," the review's authors wrote.

Similarly, maintaining between three and six feet of distance from others reduces the infection rate from 12.8% to 2.6%.

"The main benefit of physical distancing measures is to prevent onward transmission and, thereby, reduce the adverse outcomes of SARS-CoV-2 infection. Hence, the results of our current review support the implementation of a policy of physical distancing of at least 1 [meter] and, if feasible, 2 [meters] or more," according to the review.

Medical experts believe that the coronavirus typically spreads via droplets from a patient's coughs, speech, or sneezes. It's also possible fora person to never show symptoms and yet transmit the diseaseto others they come in contact with.

Some people wear masks, with others don't, in Huntington Beach, California, on April 25, 2020. Apu Gomes/AFP/Getty Images

So eye protection hasn't been a standard recommendation like regular hand-washing. But the Lancet review found that wearing goggles or a faceshield brings the transmission rate down from 16% to 5.5%.

"The use of a mask alone is insufficient to provide an adequate level of protection or source control, and other personal and community level measures should also be adopted to suppress transmission of respiratory viruses," the WHO said. "Whether or not masks are used, compliance with hand hygiene, physical distancing and other infection prevention and control (IPC) measures are critical to prevent human-to-human transmission of COVID-19."

President Donald Trump's actions, however, continue to fly in the face of these findings. He refuses to wear masks in public and went so far as to poke fun at Democratic presidential nominee Joe Biden for wearing one.

Meanwhile, a study conducted by the US Navy's Bureau of Medicine and the Centers for Disease Control and Prevention found that preventative measures also lowered the infection rate among sailors on board the USS Theodore Roosevelt.

The Navy reported that out of a crew of about 4,800 sailors, 1,273 tested positive for the virus and 382 sailors participated in the study.

The results indicated that sailors who did not wear masks experienced an 80.8% infection rate, while those who used face coverings had a 55.8% infection rate. People who did not follow social distancing guidelines fell sick at a rate of 70% versus 54.7% for those who stayed around six feet away from others.

Also, sailors who used common areas reported an infection rate of 67.5% and those who avoided those spaces saw a 53.8% infection rate.

The Navy also reported that 18.5% of those who came down with the coronavirus were asymptomatic so they did not fall sick at all, but were still contagious while still others had mild symptoms.

"This study shows young, healthy adults with COVID-19 might have mild, atypical, or no symptoms; therefore, symptom-based surveillance might not detect all infections. Use of face coverings and other preventive measures could mitigate transmission in similar settings," the Navy said in a statement, according to the San Diego-Union Tribune.

These findings were echoed by a British study, led by scientists at Cambridge and Greenwich universities, which concluded that lockdowns alone cannot prevent surges in coronavirus cases and deaths.

"Our analyses support the immediate and universal adoption of face masks by the public," Richard Stutt, who co-led the study at Cambridge, Reuters reported.

Stutt added that masks, social distancing, and other containment measures could be "an acceptable way of managing the pandemic and re-opening economic activity" as companies race to develop a vaccine against COVID-19.

The spread of the coronavirus disease (COVID-19), in Fayetteville Nick Oxford/Reuters

This study appeared in a scientific journal called Proceedings of the Royal Society A, with authors writing that "when facemasks are used by the public all the time (not just from when symptoms first appear), the effective reproduction number, [R value], can be decreased below 1, leading to the mitigation of epidemic spread."

The R value indicates how contagious an infectious disease is.An R value above 1 can trigger exponential growth of a virus, per Reuters. In the case of the coronavirus, studies so far suggest that on average patients infect 2 1/2 other people.

So, the study says, "face mask use by the public could significantly reduce the rate of COVID-19 spread, prevent further disease waves and allow less stringent lock-down regimes. The effect is greatest when 100% of the public wear face masks."

A study that was published by the nonprofit Institute of Labor Economics (IZA) investigated the German city of Jena and arrived at similar conclusions about the efficacy of face masks.

"After face masks were introduced on 6 April 2020, the number of new infections fell almost to zero," the authors wrote, adding that the face coverings were most helpful in curbing the infection rate among people who were above 60 years old.

"We believe that the reduction in the growth rates of infections by 40% to 60% is our best estimate of the effects of face masks . . . We should also stress that 40 to 60% might still be a lower bound," they added.

The study went on to say that masks could have made a more significant impact if they had been used earlier and more widely. It wasn't until April 20 and April 29 that all German federal states made it compulsory to wear face coverings.

"The daily growth rates in the number of infections when face masks were introduced was around 2 to 3%," the study's authors wrote. "These are very low growth rates compared to the early days of the epidemic in Germany, where daily growth rates also lay above 50%. One might therefore conjecture that the effects might have been even greater if masks had been introduced earlier. "

Read more:
Face masks help to limit the spread of the coronavirus, research shows - Business Insider - Business Insider

Read More...

Boulder Smile Design Expands Their Team With Addition of New Pediatric Dentist, Dr. Jennifer Rubin, DMD – PR Web

June 17th, 2020 11:50 am

Dr. Jennifer Rubin, D.M.D.

BOULDER, Colo. (PRWEB) June 17, 2020

Boulder Smile Design is proud to welcome Dr. Jennifer Rubin, D.M.D. to its practice. Dr. Rubin is a board-certified pediatric dentist, allowing the practice to expand services and provide comprehensive care for its growing number of patients.

Dr. Rubin is an exceptional addition to our team, said Jesse Friedman, D.M.D., owner of Boulder Smile Design. She is an extremely skilled dentist and has a huge heart, both of which make her an amazing pediatric and special needs dentist."

Since she was a little girl, Dr. Rubin always knew she wanted to be a dentist for kids. Dr. Rubin attended Boston University, where she received a Bachelor of Science in Psychology, a Master's in Biomedical Sciences, and finally her dental degree from the Boston University Henry M. Goldman School of Dental Medicine. She graduated with magna cum laude honors. She followed that with a hospital-based General Practice Residency at New York Presbyterian-Weill Cornell Hospital in New York City and then completed her residency in pediatric dentistry at Mount Sinai Hospital in New York City as well. In addition to her range of dental service expertise, Dr. Rubin is an active member in the Boulder dental community, volunteering with a number of local organizations and regularly visiting local schools and daycare centers to educate children. She is a member of the American Dental Association, the Colorado Dental Association, and the Metro Denver Dental Society. She is board certified from the American Board of Pediatric Dentistry and also maintains an active membership with the American Academy of Pediatric Dentistry. She takes continuing education classes every chance she gets and stays up-to-date on the latest in pediatric and special needs care.

I wanted to join Boulder Smile Design because I knew that the levels of care matched my own rigorous standards, said Dr. Rubin. They have always provided exceptional dentistry in Boulder. I absolutely love taking care of children, and I treat for each one like my own.

Boulder Smile Design has provided high-end dental care for families in the area for nearly 50 years, with just over 10 in its current location. All dentists in the office work to understand individual patient dental needs and use state-of-the-art materials and equipment to achieve these goals. Services are comprehensive and range from ongoing preventative care to emergency dentistry services. Patients of all ages count on the dental cleaning and checkup services to prevent cavities, avoid gum disease, and boost overall health. The office uses absolutely no amalgam or mercury fillings; resin composite (white fillings) and sealant services provide further proactive and restorative dental care to ensure the ongoing health of each tooth and patient. Advanced restorative and prosthodontic services, such as crowns, bridges, porcelain veneers, and dental implants are also available to provide natural-looking improvements for stained, chipped, decayed, damaged, or broken teeth. The dentists stay up-to-date with a variety of continuing education, including sleep medicine, sleep apnea, and sleep-disordered breathing; craniofacial growth, cosmetic dentistry, laser technology, orthodontics, and complex rehabilitative care. The dentists employ a range of digital technology, including 3-D oral scanners, ultra-low-radiation digital x-rays, and the newest and most advanced equipment for diagnosing and treating disease.

The dentists at Boulder Smile Design take their role and engagement in the community seriously. Each dentist has donated considerable pro bono dental work for a range of non-profit organizations including Give Kids a Smile, the Dental Lifeline Network, and the Colorado Mission of Mercy. The professionals in the practice understand the important role dental health and esthetics play in both overall wellness and confidence in life.

We have a responsibility for our patients and our city, Dr. Friedman said. We view every day as an opportunity to give our very best to patients and the community overall. Every single person should have the opportunity to receive phenomenal care in a comfortable, relaxing, stress-free environment.

Boulder Smile Design is open Mondays, Tuesdays, and Thursdays from 7-5; Wednesdays from 7-3; and select Fridays and Saturdays. Call to ask about your dental insurance. It is located at 3000 Center Green Drive, Suite 215, Boulder, CO 80301. Learn more about Boulder Smile Design at http://www.bouldergeneraldentist.com or call for an appointment (303) 442-6142.

Share article on social media or email:

Continue reading here:
Boulder Smile Design Expands Their Team With Addition of New Pediatric Dentist, Dr. Jennifer Rubin, DMD - PR Web

Read More...

Digital healthcare and rising cyber concerns – TheDispatch

June 17th, 2020 11:50 am

The outbreak of COVID-19 has not only pushed economies into recession but also brought forth the fragility of healthcare systems in general. Migrating to digital mode has since been a major move across the healthcare sector. Increased digitalisation is expected to help service providers create a robust and critical infrastructure focused on patients safety and quality care. The future of digital healthcare appears promising as patients would be more comfortable using digital services for complex and sensitive medical conditions. However, a major downside of going digital is the imminent threat of attacks lingering in the cyberspace. Considering that the healthcare sector is critical infrastructure, patient information and medical reports available online would be a gold trove that could be exploited for various malicious purposes.

Digital healthcare refers to the integration of medical knowledge with information technology (IT) applications (apps) to help improve medical care and supervision of patients. This means that a smartphone can be used to determine patients medical condition by monitoring patients vital data (pulse, blood pressure and oxygen saturation) including body temperature and movement patterns. It can also be used to determine if the patient has taken the prescribed medication.

Digital technologies enable need-oriented solutions and the provision of preventative, clinical and rehabilitative services. Deploying advanced technologies like digital health, big data, artificial intelligence (AI), augmented reality (AR) and virtual reality (VR), wearables and internet of things (IoT), 3D printing technology and so on would impact different forms of treatment, care concepts, and image of the medical profession and role of patients. In terms of IT strategy, many of these areas relate to opportunities for the formulation of hospital processes subject to the concept of hospital 4.0. New diagnostic and therapeutic approaches are developed with the support of IT management in the context of precision medicine approach and digital therapeutics that powers personalised predictive care.

Todays telehealth technology is empowering patients in the remotest locations of the world to access quality healthcare and receive life-saving diagnoses. Telemedicine allows access to quality healthcare at any time thereby levelling the playing field geographically and financially. Additionally, it has been observed that using AI and deep learning, body scans have been shown to analyse CAT scans up to 150 times faster than human radiologists, detecting acute neurological events in just 1.2 seconds.With several medical-grade sensors including optical, temperature, electrodermal, accelerometer and barometer being incorporated within wearables, these devices can be comfortably worn on the arm for several days and have higher-than-average patient satisfaction and adherence rates. The data from these wearables can be used in effective ways like monitoring health and providing preventative care. For instance, Hong Kong has been putting electronic wristbands on arriving passengers to enforce the coronavirus quarantine.The wristbands are connected to a smartphone app to make sure that people stay at home and break the chain of further spread of the virus.

There has been a slew of technologies deployed to check the spread of COVID-19 like contact tracing apps, electronic fences, robots, and infrared (IR) thermal screening. These technologies that aid round-the-clock remote monitoring and analytics are providing clinicians with decision support for early identification of any physiological alterations that could indicate deterioration, and facilitating early interventions for better outcomes.It has been predicted that by 2025 most of the hospitals worldwide would move to the digital platform, thereby increasing the market size of the healthcare sector from US$ 16.92 billion in 2017 to about US$ 58.78 billion by 2025.However, there is an evident downside to these healthcare innovations. These new devices open-up more entry points of cyberattacks and challenges for those in charge of online security and patient data protection.

The healthcare sector has been the prime target of online attacks threatening day-to-day work and compromising confidential patient data. The critical infrastructure systems in hospitals are particularly threatened by ransomware, besides different types of malware and distributed denial of service (DDoS) attacks, which can be locked up by malicious actors and unlocked only following payment of ransom.

Security researchers in Israel have been able to create malwares capable of adding tumours into CAT and MRI scans and misleading doctors into misdiagnosing high-profile patients.Another reason for increased attacks is the availability of enormous patient data that is worth a lot of money. Nefarious actors sell the data to counterfeiters who then produce genuine-looking insurance claims. Tampering of health and personal data like medical history, allergies, and medications can have dire consequences.

Medical devices are designed for one-point tasks like monitoring of heart rates or dispensing drugs. They are not designed with security in mind. Although the devices themselves may not store the patient data that attackers pursue, they can be used as launching grounds to attack a server that holds valuable information, or facilitates access to other networks, or let hackers install expensive ransomware on servers. In a worst-case scenario, medical equipment can completely be overridden by attackers, limiting hospitals from providing vital life-saving treatment to patients.

Since 2009, medical data theft has occurred either by stealing laptops or hard drives or identifying and stealing passwords. However, in recent years, myriad cyberattacks have compromised millions of medical records and patients personal information. For instance, in 2018, the MGM Hospital in Vashi, Mumbai fell victim to a cyberattack that locked the hospital data and demanded a ransom in bitcoins.Similar incidents of WannaCry, Petya and NotPetya ransomware attacking the healthcare sector have been reported from many countries, notably the 2017 attack on the United Kingdoms National Health Service (NHS) where more than 70,000 devices like laptops, desktops and medical machinery were infected with attackers demanding ransom in cryptocurrency to decrypt the encrypted data of the hospitals.

In the backdrop of COVID-19, many healthcare organisations have seen an increase in cyber exploitation. According to a report, the cyberattacks in the healthcare sector increased by 150 per cent during January-February 2020 as criminals sought to take advantage of the system vulnerabilities during the crisis.Scams by grey-marketers for personal protective equipment (PPE) have also seen a steady rise as healthcare professionals remain short of critical supplies.

On March 13, 2020, one of the Czech Republics biggest testing laboratories, Brno University Hospital, was hit by a cyberattack. As a result, the hospital had to postpone urgent surgical interventions and transfer patients with acute conditions to a different hospital while shutting down their entire IT network.Similarly, the website of Champaign-Urbana Public Health District in the United States was attacked by new ransomware called NetWalker.Victims received a ransom demand for the encryption key to regaining access to their data. This ransomware camouflaged itself within essential Windows functions to evade anti-virus detection. Health district employees became aware of the ransomware attack on March 10 when they lost access to the medical files. The Federal Bureau of Investigation (FBI) thereafter issued a warning about Kwampirs (a backdoor Trojan that grants remote computer access to the attackers) malware targeting supply chains including the healthcare industry.

Microsoft has also been warning healthcare organisations to watch out for sophisticated ransomware attacks that could target them through their virtual private networks (VPNs) and other network devices. In particular, Microsoft warned about ransomware campaign called REvil (also known as Sodinokibi), which actively exploits gateway and VPN vulnerabilities to gain a foothold in the target organisations.After successful exploitation, attackers steal credentials, elevate their privileges and move laterally across compromised networks, installing ransomware or other malware payloads.

India has not been very far behind in riding the digital wave. In 2017, the union cabinet approved the formulation of National Health Policy, under which a National e-Health Authority (NeHA) is to be setup.Such a policy would evolve and expand health information networks across the continuum of care, such as e-Health, m-Health, and cloud technology and IoT in healthcare delivery. Major IT initiatives include India Fights Dengue mobile app which provides interactive information on the identification of symptoms and links users to the nearest hospitals and blood banks. TheSwasth Bharat(Healthy India) app provides information on healthy lifestyle, disease conditions and their symptoms, treatment options, and first aid and public health alerts.Through theKilkarimobile app initiative, audio messages about pregnancy as well as childbirth and child care are directly sent to the families and parents. A mobile-based audio training course has been developed for expanding the knowledge base of the rural voluntary health workforce. Other m-Health applications include National Health Portal, Online Registration System, E-Rakt Kosh, ANM Online (ANMOL), telemedicine projects (in remote and inaccessible areas), Tobacco Cessation Programme and leveraging mobile phones for reaching out to the tuberculosis patients.

The Ministry of Health and Family Welfare introduced a draft bill on Digital Information Security in Healthcare Act (DISHA) in March 2018.One key purpose of the proposed bill is to secure and create reliable storage of healthcare data. It will help constitute a health information exchange, as deemed eligible by the Act, and maintain the digital healthcare data of individual patients. The central government plans to incorporate a database to store information of patients and other health system components at the district and national-levels (National Health Information Network) which is expected to be implemented by 2020 and 2025, respectively.A key suggestion is to link Aadhaar to the health information network so that the patient identification works seamlessly. It also includes the participation of the private sector in developing a common network to help in accessing information by both public and private healthcare providers.

With the allocation of funds in the 2019 union budget for theAyushman Bharat Yojana,developing the healthcare sector is a top priority. Meanwhile, to ensure better coverage for the healthcare initiative, the Ministry of Health has issued a critical document for public consultation to completely digitalise the healthcare data, and create a national digital health network called National Digital Health Blueprint.This would help deliver value-added services to the concerned users with a consent-based flow of citizens health record.

India is committed to financially support all the digital initiatives and looks for multi-stakeholder engagement and private-public partnerships to scale up these initiatives. Even under the current crisis, the government has rolled out apps such asAarogya Setuto help citizens identify the risk of contracting COVID-19 andAYUSH Sanjivanito spread awareness about traditional Ayurvedic medicines.

Going digital is the most effective way to protect the first line of healthcare workers especially in the case of highly communicable viruses like COVID-19 while increasing the efficiency of health services. However, cybersecurity cannot be an afterthought in the healthcare sector. Medical specialists often use old and outdated software/hardware with minimum security features, staff lacks the necessary security know-how to implement updates and patches promptly, and many medical devices lack security software altogether. Human error opens a hole in systems as most breaches are triggered by employee mistakes or unauthorised disclosures. Experts note that hospitals often do not know what systems run on the devices they use. Many of these devices are black boxes to hospitals as there is a general lack of awareness, besides the usual lack of resources. Without a multi-layered protective cyber ecosystem, the medical staff may not even know when they are under attack.

India is at the cusp of digital transformation. However, with digital threats becoming trickier, a more holistic approach towards cybersecurity would be needed to facilitate the creation of a vibrant digital healthcare environment. If going digital is necessary for the country to be on par with the digital world, then building a resilient and trusted cyber ecosystem is also a necessity.

Research Analyst at Manohar Parrikar Institute for Defence Studies and Analyses.

Visit link:
Digital healthcare and rising cyber concerns - TheDispatch

Read More...

Lords seek to allow gene-editing in UK ‘to produce healthy, hardier crops’ – The Guardian

June 17th, 2020 11:49 am

Peers are preparing plans to legalise the gene-editing of crops in England, a move that scientists say would offer the nation a chance to develop and grow hardier, more nutritious varieties. The legislation would also open the door to gene-editing of animals.

The change will be proposed when the current Agriculture Bill reaches its committee stages in the House of Lords next month, and is supported by a wide number of peers who believe such a move is long overdue. At present, the practice is highly restricted by EU regulations.

The plan would involve introducing an amendment to the bill to give the secretary of state for environment, food and rural affairs the power to make changes to the Environmental Protection Act, alterations that would no longer restrict gene-editing in England. The rest of the UK would need separate legislation.

Gene-editing of plants and animals is controlled by the same strict European laws that govern genetically modified (GM) organisms. However, scientists say gene-editing is cheaper, faster, simpler, safer and more precise than GM technology.

As they point out, GM technology involves the transfer of entire genes or groups of genes from one species to another while the more recently developed techniques of gene-editing merely involve making slight changes to existing genes in a plant or animal and are considered to be just as safe as traditional plant breeding techniques.

Early benefits for UK agriculture could include gluten-free wheat, disease-resistant sugar beet and potatoes that are even healthier than those that we have now, said plant scientist Professor David Baulcombe of Cambridge University.

This enthusiasm is also shared by peers who have argued that the wide use of gene editing of crops could give the nation a key advantage in agriculture and in the food industry after Brexit.

Peers have argued gene editing could give the nation a key advantage after Brexit

I would like [to send] a clear message in this bill that we will move forward to allow gene editing in our research programmes, said Lord Cameron during last weeks reading of the bill. This is a way of speeding up the natural methods of farm breeding to ensure that we can improve the environmental and nutritional outcomes of feeding our ever-expanding human population.

And there was clear evidence that the government would also be sympathetic to such a move. On gene editing, the government agrees that the EU approach is unscientific, said Lord Gardiner, who was responding for the government.

By freeing gene-editing from the expensive restrictions imposed by the EU on the growing of GM plants it will also be possible for small and medium-sized enterprises to set up new projects, say supporters.

At present only major corporations can pay the costs of the rigorous trials required when growing GM plants. We are looking for a brighter, greener, more innovative future, and this bill helps farmers produce that, said Conservative peer Lord Dobbs last week.

Read more here:
Lords seek to allow gene-editing in UK 'to produce healthy, hardier crops' - The Guardian

Read More...

2025 Projection: Genetic Engineering Market Strategies and Insight Driven Transformation 2020-2025 – Owned

June 17th, 2020 11:49 am

Research report on global Genetic Engineering market 2020 with industry primary research, secondary research, product research, size, trends and Forecast.

The report presents a highly comprehensive and accurate research study on the globalGenetic Engineering market. It offers PESTLE analysis, qualitative and quantitative analysis, Porters Five Forces analysis, and absolute dollar opportunity analysis to help players improve their business strategies. It also sheds light on critical Genetic Engineering Marketdynamics such as trends and opportunities, drivers, restraints, and challenges to help market participants stay informed and cement a strong position in the industry. With competitive landscape analysis, the authors of the report have made a brilliant attempt to help readers understand important business tactics that leading companies use to maintainGenetic Engineering market sustainability.

Download Premium Sample Copy Of This Report:Download FREE Sample PDF!

Global Genetic Engineering Market to reach USD XX billion by 2025.

Global Genetic Engineering Market valued approximately USD XX billion in 2017 is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2018-2025. The major driving factor of global Genetic Engineering market are surging utility of technologies such as CRISPR, Talen & ZNF and rising focus on innovation in Gene Therapy in Genetic Engineering. In addition, increasing funding for research and development of medical products is the some other driving factor that drives the market. However, one of the major restraining factors of Genetic Engineering market is high amount of investment. Genetic engineering is also known as genetic modification or genetic manipulation. It is the direct manipulation of an organisms genes using biotechnology. It is a set of technologies used to change the genetic makeup of cells, including the transfer of genes within and across species boundaries to produce improved or novel organisms. Genetic engineering allows of plant or animals to be modified so their maturity can occur at a quicker pace. Genetic modification can also help to create resistance to common forms of forms of organism death. Genetic engineering can also change the traits of plants or animals so that they produce greater yield per plant. Any genetic mutation caused by environmental mutagens may also be corrected through genetic engineering.

The regional analysis of Global Genetic Engineering Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America has dominate the market of total generating revenue with 40% across the globe in 2016 due to increasing use of genetic engineering for use of gene therapy, high incidence of cancer and increasing awareness for the use of stem cells. Europe is also contributing second largest major share in the global market of Genetic Engineering. Asia-Pacific region is also anticipated to exhibit higher growth rate / CAGR over the over the coming years due to presence of developing countries, companies grabbing these opportunities and extracting their presence in the region. The Middle East and Africa holds the least share in global genetic engineering market owing to limited availability of medicine facilities.

The major market player included in this report are:

Thermo Fisher Scientific Inc.

Merck KGAA

Horizon Discovery Group Plc

Transposagen Biopharmaceuticals Inc.

New England Biolabs

Genscript Biotech Corporation

Lonza Group Ltd.

Origene Technologies Inc.

Integrated DNA Technologies Inc.

Amgen Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Devices:

oPCR

oGene Gun

oGel Assemblies

oOthers

By Techniques:

oArtificial Selection

oGene Splicing

oCloning

oOthers

By End-User:

oResearch Institutes

oAcademic Institutes

oPharmaceutical Industries

oOthers

By Application:

oAgriculture

oMedical Industry

oForensic Science

oOthers

By Regions:

oNorth America

oU.S.

oCanada

oEurope

oUK

oGermany

oAsia Pacific

oChina

oIndia

oJapan

oLatin America

oBrazil

oMexico

oRest of the World

Furthermore, years considered for the study are as follows:

Historical year 2015, 2016

Base year 2017

Forecast period 2018 to 2025

Target Audience of the Global Genetic Engineering Market in Market Study:

oKey Consulting Companies & Advisors

oLarge, medium-sized, and small enterprises

oVenture capitalists

oValue-Added Resellers (VARs)

oThird-party knowledge providers

oInvestment bankers

oInvestors

Have Any Query Or Specific Requirement?Ask Our Industry Experts!

Table of Contents:

Study Coverage:It includes study objectives, years considered for the research study, growth rate and Genetic Engineering market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary:In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Genetic Engineering market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Genetic Engineering Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region:It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://brandessenceresearch.com/healthcare/radiotherapy-market-global-size

https://brandessenceresearch.com/technology-and-media/lease-accounting-software-market

Top Trending Reports:

https://www.marketwatch.com/press-release/europe-composite-materials-market-global-industry-analysis-and-opportunity-assessment-2020-2025-2020-06-15?tesla=y

https://www.marketwatch.com/press-release/europe-composite-materials-market-global-industry-analysis-and-opportunity-assessment-2020-2025-2020-06-15?tesla=y

https://www.marketwatch.com/press-release/europe-composite-materials-market-global-industry-analysis-and-opportunity-assessment-2020-2025-2020-06-15?tesla=y

https://www.marketwatch.com/press-release/europe-lipid-nutrition-market-size-growth-opportunity-and-forecast-to-2025-2020-06-09

Continued here:
2025 Projection: Genetic Engineering Market Strategies and Insight Driven Transformation 2020-2025 - Owned

Read More...

Swiss men aspire to live to 108.5 years old – swissinfo.ch

June 17th, 2020 11:49 am

Swiss men have targeted an ideal lifespan of 108.5 years, while women are content with an average of 93.4 years of life. A survey of 2,000 people by the health insurer Sanitas found that many people are making changes to their lifestyle to secure a longer life.

swissinfo.ch/mga

Two thirds of respondents said they are physically active and eat healthy food while more than half refrain from smoking and a fifth abstain from alcohol.

The Health Forecast survey, which aims to come out annually, found that 40% of people currently use an app to monitor their health. More than a quarter of respondents would employ blood and DNA tests to determine optimal nutritional supplements and other tailor-made fitness measures.

Young men, in the 18-29 age range, appear keener than anyone else to actively boost their health and fitness levels. A third of male respondents in this age group (compared to 20% of all ages and genders) would consider biohacking a buzzword that involves enhancing health via diet, exercise, wearables and sometimes implants, such a microchips, or genetic engineering.

Only half as many women in this age group said they would be prepared to go to such lengths.

The survey also reveals more detail on attitudes to genetic science. Some 58% support gene therapy to treat cancer, 54% are in favour of gene diagnostics to diagnose hereditary diseases and 44% welcome prenatal screenings.

But three-quarters of respondents said this science should stop short of active intervention by altering genes or producing clones.

View original post here:
Swiss men aspire to live to 108.5 years old - swissinfo.ch

Read More...

Mosquitoes can be genetically engineered to be resistant to malaria – Massive Science

June 17th, 2020 11:49 am

Our relationship to Neanderthals has been a point of contention for over a century. It all began with an inaccurate reconstruction of the first Neanderthal ever found, which portrayed them as brutish, stooped-over cavemen (turns out, that Neanderthal was an injured old man with arthritis).

But within the last half century, scientists have noticed the many biological and behavioral similarities that show just how close our species are. While these similarities are clear from hard objects like bones and tools, perishable objects, which comprise the majority of material culture items in humans, have been lacking.

Now, scientists have discovered a Neanderthal feat that hammers another nail in the coffin of supposed Neanderthal inferiority. Last month, an international team of researchers found a small section of a twisted cord attached to a stone flake in Neanderthal site in southeastern France, dated to over 40,000 years old. This constitutes the oldest direct evidence of fiber technology ever found.

A stone flake with three distinct twisted fibers preserved (indicated by the box).

M.-H. Moncel

When artifacts are recovered from archaeological sites, they are generally imaged using high powered microscopes to zoom in on tiny marks and details on the stones. Previously, plant fibers had been found on stones at this site, but they were too poorly preserved to be interpreted. When the team examined this particular flake, they were surprised to find three distinct twisted fibers, which were then twisted together in the opposite direction to form a 3-ply cord.

While it may not sound like much, this piece of string hints at something much more significant. For one, extracting and manipulating plant fibers requires working memory, as well as understanding plant seasonality and the concept of numbers. Also, such cords are the building blocks for creating other textiles, such as baskets, fabrics, and nets. Once adopted, these objects would have been indispensable in daily life.

This little piece of string provides unprecedented insight into the lives of our extinct relatives, which, despite an abundance of genetic, archaeological, and skeletal data, have been extremely difficult to interpret. It seems as though we humans arent as unique as we like to think.

Read the rest here:
Mosquitoes can be genetically engineered to be resistant to malaria - Massive Science

Read More...

Page 494«..1020..493494495496..500510..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick